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Abstract 
Under certain regimens of repeated pre-exposure, psychostimulant drugs show 
an increase in locomotor activity across days of testing and, after abstinence 
from the drug, a greater responsiveness to a subsequent challenge dose of the 
drug. This phenomenon, termed behavioural sensitisation, is thought to 
underlie certain aspects of drug addiction such as drug seeking and relapse. 
Repeated administration of +/-3, 4-Methylenedioxymethamphetamine 
(MDMA, ecstasy) produced sensitised hyperactivity in rats suggesting a lasting 
neurological change. The present studies sought to evaluate some of the 
parameters around both the induction and expression of behavioural 
sensitisation to MDMA and to evaluate if the sensitivity of the dopamine (DA) 
D1 and D2 receptors had altered under the current pre-exposure regimen of 
MDMA. Further, following MDMA pre-exposure that results n behavioural 
sensitisation, changes in potency to the reinforcing effects of MDMA were 
investigated through the self administration paradigm. Finally, high 
performance liquid chromatography (HPLC) was used to evaluate changes in 
brain amine levels following sensitisation to MDMA locomotor activating 
effects. 
 
Rats received a pre-treatment regimen consisting of 5 daily injections of 
MDMA (0.0, 5.0 or 10mg/kg i.p). MDMA-produced locomotor activity was 
measured after 2, 9 or 28 days of withdrawal. In other groups, hyperactivity 
following administration the DA D1 agonist SKF81297 (0.0, 0.5, 1.0, 2.0, 4.0 
or 8.0 mg/kg), or the D2-like DA agonist apomorphine (0.0, 0.5, 1.0, 2.0 or 4.0 
mg/kg) was measured in groups that received pre-exposure to MDMA (10.0 
 4 
mg/kg) or vehicle. The effects of the D1 antagonist SCH23390 (0.0, 0.01, 0.02, 
or 0.04 mg/kg), the D2 antagonist eticlopride (0.03, 0.01, 0.003, 0.05, 0.1, or 
0.2 mg/kg) or the 5-HT2C antagonist RS102221 (0.0, 0.25, 0.5, or 1.0 mg/kg) 
on MDMA-produced hyperactivity in MDMA or vehicle pre-treated rats was 
also measured. In Experiment 3, effects of MDMA or vehicle pre-treatment on 
latency to acquisition of MDMA (0.5 or 1.0 mg/kg/infusion) self-
administration was measured. In Experiment 4 effects of pre-treatment on brain 
tissue levels of  DA, its metabolite homovanillic acid (HVA), serotonin (5-HT) 
and its metabolite, 5-hydroxyindoleacetic acid (5-HIAA) were determined.  
 
The regimen of 5 daily treatments of 10.0mg/kg produced persistent 
behavioural sensitisation and cross-sensitisation to hyperactivity produced by 
DA receptor agonists. These effects were not, however, reflected in sensitised 
responses to the ability of the antagonists to attenuate MDMA-produced 
hyperactivity. Pre-treatment with MDMA did not decrease latency to 
acquisition of self-administration. Rather, there was an increased latency to 
acquisition of self-administration in the MDMA pre-treated rats. MDMA pre-
treatment decreased levels of the serotonin metabolite 5-HIAA in the frontal 
cortex and hippocampus. Following the current pre-treatment regimen, MDMA 
produced behavioural sensitisation is mediated by neuroadaptations in central 
dopaminergic substrates. The persistent locomotor sensitisation is similar to 
that produced by other amphetamine-like stimulants and might underlie use 
and abuse of this compound.  
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MDMA 
 
The amphetamine derivative, 3, 4-methylenedioxymethamphetamine 
(MDMA or ‘ecstasy’) was synthesised around 1912 and a patent was 
granted in 1914 (Green, Mechan, Elliott, O'Shea, & Colado, 2003; 
Kalivas, Duffy, & White, 1998). It is chemically similar to 
amphetamine, methamphetamine, mescaline (see figure 1) and a 
number of ring-substituted phenethylamines and is both a stimulant and 
hallucinogenic compound (Battaglia, Brooks, Kulsakdinun, & De 
Souza, 1988; Baumann, Wang, & Rothman, 2006; Gold, Koob, & 
Geyer, 1988).  
 
 
Figure 1.chemical structure of Amphetamine, mescaline and MDMA. 
 
Research in the early part of the 20th century is scant but the LD 50 
(the Lethal Dose in 50% of animals tested) was investigated by the U.S. 
military in the 1950s. During the early 60s it was reportedly first used 
recreationally (Watson & Beck, 1991). In the 1980’s it was used as an 
adjunct to psychotherapy before the U.S. drug enforcement 
administration changed its classification to a schedule 1 drug and 
hence, illegal (Green, et al., 2003). 
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MDMA was a popular recreational drug in the United Kingdom in the 
1980’s (Cole and Sumnall, 2003) with popularity of the drug increasing 
during the 1990’s leading to more widespread use. A number of survey 
studies have suggested increased use throughout the 1990s depending 
upon the population sampled. For example, in a sample of 158 current 
drug users 82% said that they had used MDMA in the previous year 
(Williamson, et al., 1997) while only 4% of medical students surveyed 
at, or near, the same time reported MDMA use (Webb, Ashton, Kelly, 
& Kamali, 1998). The same authors reported 13% use by UK university 
students while U.S. student’s use increased from 2.8% in 1997 to 4.7% 
in 1999 and 10.6% in the final 2000 survey (Strote, Lee, & Wechsler, 
2002). 
 
The United Nations Office on Drugs and Crime (UNODC, 2004) 
presented long-term worldwide trends in production, trafficking and 
abuse of drugs. The reports revealed that the consumption of certain 
illicit drugs such as heroin and cocaine were decreasing while during 
the last previous decade, amphetamine-type stimulants (mainly 
MDMA) were the second most commonly used illicit drug. 
 
In New Zealand, the Expert Advisory Committee on Drugs reported an 
increase in overall use. Those who positively responded to the question, 
“had they ever used MDMA?” increased from 3% - 5.4% between 
1998 and 2001. The greatest reported use, as well as greatest increase 
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in use, came from the 20-24 year age group of survey respondents. In 
this age group, use of MDMA during the previous 12 months rose from 
3%-10% between 1998 and 2001 (The Expert Advisory Committee on 
Drugs [EACD], 2004). These figures put New Zealand on a roughly 
equal footing, in terms of use, with other overseas sample results. 
 
Consistent with the reported increases of use have been increases in 
associated medical complications. MDMA induces a number of serious 
effects such as cardiac arrhythmias, hypertension, hyperthermia, 
hyponatremia (disturbance of the salts in the blood), liver 
complications, seizures and coma (Schifano, 2004). Deaths attributable 
to ecstasy use are rare but they are increasing. In the U.K., out of all the 
drug related deaths, ecstasy use in 1997 accounted for 1.2% rising to 
4.1% in 2002 (Schifano, Corkery, Deluca, Oyefeso, & Ghodse, 2006). 
 
MDMA Pharmacology 
 
MDMA is a racemic molecule in that it has two enantiomers. The 
(S)(+)-enantiomer is a more potent dopamine releaser while the (R)(-)-
enantiomer shows a higher affinity for serotonin receptors (Johnson, 
Hoffman, & Nichols, 1986).  MDMA is usually formulated and 
consumed as a racemate, a 1:1 mixture of its enantiomers (Pizarro, et 
al., 2004) and acts on a number of different neurochemical systems 
releasing presynaptic serotonin (5-HT), dopamine (DA) and 
norepinephrine (NE). MDMA induces increases in extracellular 
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monoamine concentrations through three direct actions (Cole & 
Sumnall, 2003):  
 
Firstly, MDMA is a substrate for the serotonin (SERT), dopamine 
(DAT) and norepinephrine (NET) transporters binding to, and blocking 
the transporter. As presynaptic plasma membrane transporters rapidly 
remove the released monoamine from the synapse, blockage of this 
process increases extracellular levels of all the monoamines (Colado, 
O'Shea, & Green, 2004; Gough, Ali, Slikker, & Holson, 1991; Green, 
et al., 2003; Lyles & Cadet, 2003; S. R. White, Obradovic, Imel, & 
Wheaton, 1996). Evidence of the transporter interactions of MDMA 
can be seen when serotonin selective reuptake inhibitors (SSRIs), such 
as fluoxetine, when co-administered with MDMA, attenuate increases 
in 5-HT (Berger, Gu, & Azmitia, 1992; Hekmatpanah & Peroutka, 
1990; Rudnick & Wall, 1992). Similarly, the DA reuptake inhibitor, 
GBR12909, prevented MDMA induced DA release in-vitro (Koch & 
Galloway, 1997) as well as in-vivo (Nash & Brodkin, 1991) . In 
addition, extracellular norepinephrine (NE) levels were reduced by co-
administration of the NE-uptake blocker, desmethylimipramine 
(Fitzgerald & Reid, 1990). 
 
Secondly, when MDMA binds to the SERT it also induces a carrier 
mediated release of neurotransmitter. MDMA enters presynaptic nerve 
cells through passive diffusion across the membrane wall (Rudnick & 
Wall, 1992) and through the actions of the SERT into the cell nerve 
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endings (Crespi, Mennini, & Gobbi, 1997). Once inside the cell, 
MDMA induces a mechanism of calcium independent release of 
serotonin into the synapse, by preventing the repackaging of cytosolic 
5-HT into vesicles through the reversal of vesicular (Rudnick & Wall, 
1992, 1993) and plasma membrane(Iravani, Asari, Patel, Wieczorek, & 
Kruk, 2000).  
 
Thirdly, MDMA inhibits monoamine oxidase (MAO). MAO is an 
enzyme with two subtypes; MAO-A is found in the extracellular fluid, 
and MAO-B is located in the cytosolic fluid (Westlund, Denney, 
Kochersperger, Rose, & Abell, 1985). Both MAO-A and MAO-B were 
inhibited by in-vitro application of MDMA although, there was a 
preferential effect on MAO-A (Gu & Azmitia, 1993; Leonardi & 
Azmitia, 1994). The consequence of this effect of MDMA resulted in 
high extracellular levels of 5-HT and a greater level of intracellular 5-
HT available for reverse vesicular transport.  MAO-A also plays a 
central role in metabolising serotonin, norepinephrine and dopamine 
(Kato, Dong, Ishii, & Kinemuchi, 1986). Extracellular increases in the 
monoamines are thereby also produced by MAO inhibition. 
 
A linear proportional increase in MDMA-produced DA occurred with 
increasing levels of 5-HT (Jacocks & Cox, 1992; S. R. White, Duffy, & 
Kalivas, 1994) suggesting that increases in extracellular 5-HT may 
trigger DA release via interaction with receptors. There are at least 14 
distinct 5-HT receptors belonging to seven families [5-HT1 through 5-
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HT7] (Hoyer, Hannon, & Martin, 2002) with the 5-HT1B, 5-HT2A, 5-
HT2C, 5-HT3 and 5-HT4 receptors all involved in the modulation of DA 
release. Of particular interest, activation of the 5-HT2A and 5-HT2C 
receptors produce opposite effects on DA release. Systemic 
administration of the 5-HT2A receptor antagonist ketanserin, and the 
selective 5-HT2A antagonist MDL100,907 attenuated MDMA-induced 
increases in striatal dopamine efflux (Nash, 1990; Schmidt, Abbate, 
Black, & Taylor, 1990). In contrast, the selective 5-HT2C receptor 
agonist, RO 60-0175, decreased DA release (Di Matteo, 2000) while 
the receptor antagonist, SB 243213, increased DA release (Berg, et al., 
2006). These results suggest that in addition to MDMA induced DA 
release through DAT function, secondary actions of 5-HT also 
contribute to extracellular DA increases. 
 
The deleterious effects of MDMA  
 
There have been numerous investigations of the long term effects of 
MDMA in guinea pigs (Battaglia, Brooks, et al., 1988), dogs 
(Nishisawa, Mzengeza, & Diksic, 1999), non-human primates 
(Frederick, et al., 1995), chickens (Bronson, Jiang, Clark, & DeRuiter, 
1994) and  rats (e.g. Commins, et al., 1987; Malpass, White, Irvine, 
Somogyi, & Bochner, 1999; Marston, Reid, Lawrence, Olverman, & 
Butcher, 1999). 
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It has long been noticed that the sensitivity to the neurotoxic effects of 
amphetamine derivatives such as MDMA differs across mammalian 
species. Primates are more vulnerable to substituted amphetamines than 
rats or guinea pigs whereas mice are remarkably tolerant (Stone et al., 
1987). In rats, young animals were found to be much more resistant 
against the long-term neurotoxic effects of these drugs than adult ones 
(Broening et al., 1994) and different strains of rats have displayed 
different responses to MDMA. For example, MDMA is 
demethylenated by the CYP2D1 hepatic cytochrome P450 enzymes in 
the rat (Kumagai et al., 1994). This enzyme is expressed, differentially 
in rat strain with subsequent alterations in metabolism of MDMA 
(Malpass et al., 1999). The Dark Agouti rat for example, exhibits 
enzymic deficiencies whereas the Sprague Dawley strain has more 
effective CYP2D1 enzyme capacity. 
 
Mice have also being used in  investigations of the long term effects of 
MDMA, but the pharmacological effects of MDMA appear to differ 
from those of other species studied (Green, et al., 2003; Lyles & Cadet, 
2003).  In mice, the acute effects of MDMA are similar to the rat 
(Logan, Laverty, Sanderson & Yee, 1988) however, repeated large 
doses of MDMA (3 x 50mg) produced a small prolonged fall in 5-HT 
and 5-HIAA but marked falls in DA and DOPAC (Logan et al.,1988). 
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A large number of studies have reported lasting decrements in 5-HT 
and its major metabolite, 5-hydroxyindoleacetic acid (5-HIAA); 
reductions in [3H] paroxetine binding that reflect reduced density of 
SERT; and reduced serotonergic axonal density in brain tissue 
(Gouzoulis-Mayfrank & Daumann, 2006 ; O'Shea, Granados, Esteban, 
Colado, & Green, 1998; Ricaurte, McCann, Szabo, & Scheffel, 2000).  
 
Following MDMA exposure there is a biphasic modulation of 5-HT 
and 5-HIAA. There is an initial rapid increase in extracellular 5-HT (1-
4 hours following injection) with levels returning to baseline within 24 
hours. Over a period of 3-4 days there is evidence of deficits in 5-HT 
and 5-HIAA (Battaglia, et al., 1987; Colado, Murray, & Green, 1993; 
Schmidt, 1987; Stone, Stahl, Hanson, & Gibb, 1986). These deficits 
were reported following the administration of a single moderately high 
dose of MDMA (10mg/kg) (Schmidt, 1987) or repeated low (4.0mg/kg 
twice daily for 4 days) (O'Shea, et al., 1998) or high (10-40mgkg twice 
daily) (Commins, et al., 1987) doses. 
 
Following a large dose of MDMA (20mg/kg twice daily for 4 days) a 
marked reduction in the density of uptake sites was observed (Battaglia, 
et al., 1987). A decrease in 5-HT and 5-HIAA does not, however, 
necessarily reflect axonal terminal damage. Immunocytochemical 
evidence supported the finding that neurodegeneration had occurred 
within terminal, dendritic and cell body regions (Commins, et al., 1987; 
O'Hearn, 1988).  
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MDMA induced neurotoxicity in non-human primates has also been 
reported (Fischer, Hatzidimitriou, Wlos, Katz, & Ricaurte, 1995; Insel, 
Battaglia, Johannessen, Marra, & De Souza, 1989; Ricaurte, DeLanney, 
Irwin, & Langston, 1988; Ricaurte, Martello, Katz, & Martello, 1992; 
Scheffel, Lever, Stathis, & Ricaurte, 1992). There is, however, an 
important difference between the non-human primate and rodent data. 
The dose required to induce deficits in non-human primates was less 
than that required for rodents (De Souza, Battaglia, & Insel, 1990; 
Ricaurte, 1989) and the deficits were more persistent (Hatzidimitriou, 
McCann, & Ricaurte, 1999). 
  
It is tempting, given the non-human primate data, to infer that 
comparable MDMA induced deficits are produced in humans who 
abuse MDMA. Although there are indications of MDMA induced 
deficits (McCann, Mertl, Eligulashvili, & Ricaurte, 1999; Ricaurte, 
DeLanney, Wiener, Irwin, & Langston, 1988), a history of multiple 
drug use, variables such as questionable drug purity and dosage, make 
it difficult to draw robust, transferable conclusions from these studies.  
 
Brain reward mechanisms 
 
A number of converging pieces of evidence have implicated 
mesolimbic DA in brain reward mechanisms. Single cell recordings in 
monkeys showed increased  extracellular DA levels in the ventral 
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tegmental area (VTA) upon food presentation (Schultz, Apicella, & 
Ljungberg, 1993). There were extracellular DA increases in the nucleus 
accumbens (NAc) during sex behaviour in the rat (Pfaus, et al., 1990). 
Similarly, access to water for water deprived rats, increased nucleus 
accumbens DA (Young, Joseph, & Gray, 1992). In humans, 
neuroimaging techniques have provided evidence of increased 
dopamine activity in ventral striatal areas during reward related tasks 
(Schott, et al., 2008). Taken together, this strongly suggests that DA is 
a critical neurotransmitter for the mediation of reinforcement. Animal 
models are ideally suited for delineating aspects of not only natural 
rewards such as sex, and food, but also drug induced reinforcement.  
 
The seminal work conducted by Olds and Milner (1954) showed that 
electrical brain stimulation could be powerfully reinforcing. These 
‘reward’ substrates are within the medial forebrain bundle in what has 
come to be known as the ‘reward pathway’. Subsequent studies have 
suggested that the reward pathway comprises the midbrain 
dopaminergic projections from the ventral tegmental area (VTA) into 
the nucleus accumbens (NAc) shell region and into the medial 
prefrontal cortex. Excitation and ensuing dopaminergic release from 
this system (the mesolimbic system) is critical to the acute reinforcing 
effects of drugs of abuse (Carelli, 2004; Dackis & O’Brien, 2001; Di 
Chiara, et al., 2004; Kelley & Berridge, 2002; Nestler, 2005; Robinson 
& Berridge, 1993; Salamone & Correa, 2002; Wise, 1998; Wolf, 2002). 
Indeed, nearly all drugs of abuse stimulate the release of dopamine at 
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some point along the mesolimbic pathway and, regardless of the 
specific and primary mechanism of action, all drugs of abuse activate 
dopaminergic transmission (directly or indirectly) in the nucleus 
accumbens (Di Chiara, et al., 2004; Nestler, 2005).   
 
One of the more powerful tools for measuring the reinforcing effect of 
drugs is the self-administration paradigm that allows drug-taking to be 
contingent on an operant response. In this procedure, laboratory 
animals are surgically prepared with an intravenous (IV) catheter and 
placed in an operant chamber with two response options (two levers, 
one the active lever, the other inactive). One response is associated with 
an IV infusion of a drug (active lever) the other response has no 
consequence (inactive lever). When presented with this choice, a 
significantly higher level of responding on the active lever suggests 
positive reinforcement is gained from infusion of the drug (Haney & 
Spealman, 2008). Virtually all drugs that are abused by humans are 
reliably self-administered by animals (Fischman & Schuster, 1978; 
Schuster & Thompson, 1969) and the patterns of use seen in animal 
I.V. self administration comparable to the pattern of use seen in humans 
(Gardner, 2000; Spealman & Goldberg, 1978). Thus, the self-
administration procedure provides a valid and reliable animal model of 
drug abuse liability and provides an animal model of human drug-
taking and drug-seeking behaviours (Henningfield, Cohen, & 
Heishman, 1991). 
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Under baseline conditions, responding under fixed ratio schedules 
increase as the dose of drug is reduced. It has been suggested that this 
increase in responding is compensatory and maintains a constant blood 
level of drug regardless of available dose. Disruptions to the 
mesolimbic DA system alter this pattern of drug taking. For example, 
the DA receptor blocker pimozide (Risner & Jones, 1976) or 
butaclamol (Yokel & Wise, 1976) produced dose-dependent increases 
in intravenous self administration (IVSA) of amphetamine consistent 
with a reduction in dose (Pickens & Thompson, 1968).  Dialysate 
samples taken from the nucleus accumbens during IVSA of 
amphetamine showed elevated DA levels (Ranaldi, Pocock, Zereik, & 
Wise, 1999). 
 
However, dopamine release alone cannot account for the distinction 
between occasional drug use and the chronic drug dependent state 
known as ‘addiction’. It has been suggested that drug addiction 
proceeds as a result of neuroadaptive processes in the brain reward 
system (Koob, 2006). When drugs of abuse repeatedly activate the 
reward system of the brain they induce a host of long lasting, complex 
neural adaptations that are maintained over time  ranging from hours to 
years, and perhaps a lifetime (Kauer & Malenka, 2007; Nestler, 2004). 
Adaptations of addiction have been modelled in the laboratory using 
animals (Deroche-Gamonet, Belin, & Piazza, 2004), including a 
“prominent animal model of addiction”, termed behavioural 
sensitisation (Wolf, 2002 (pg. 147)).   
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Amphetamine induced Behavioural Sensitisation  
 
Behavioural sensitisation has been studied to investigate 
neuroadaptations that occur after repeated exposure to drugs of abuse 
(Wise & Bozarth, 1987). Behavioural sensitisation is a progressive, 
long lasting increase in the psychomotor stimulating property of drugs 
of abuse that manifests itself in a number of behaviourally measurable 
ways. Various behaviours such as, sniffing, rearing and head 
movements have all been reported although it is usually measured as 
the enhanced locomotor activity following repeated exposure (Pierce & 
Kalivas, 1997; Post & Rose, 1976; Robinson, 1984; Robinson & 
Berridge, 1993; Stewart & Badiani, 1993; Wolf, 1998). 
 
Sensitisation was first reported early in the 1930’s (e.g. Downs & 
Eddy, 1932; Tatum & Seevers, 1931) although it wasn’t until the late 
1960’s and early 70’s that investigations into amphetamine induced 
behavioural sensitisation were pursued in earnest (Robinson & Becker, 
1986). Initial studies established that repeated amphetamine 
administration lead to one of two states, either tolerance or 
sensitisation. The manifestation of either condition depended upon 
manipulation of a number of factors such as dose, drug exposure, and 
time after exposure. For example, continual exposure (for a two or 
three day period), or repeated multiple high doses of amphetamine, 
resulted in tolerance to drug produced hyperactivity (Kuczenski & 
Leith, 1981). On the other hand, repeated intermittent administration 
 22 
(daily injections), of relatively low doses, induced sensitisation 
(Robinson & Kolb, 1999). A single exposure to amphetamine also 
produced sensitisation to a number of drug-produced behaviours, such 
as stereotypy (Browne & Segal, 1977; Ellison & Morris, 1981) or 
rotation (Robinson, 1984; Robinson, Becker, & Presty, 1982). Repeated 
intermittent administration has been reported to produce a more robust 
and progressive increase in behaviour indicative of behavioural 
sensitisation (Kalivas & Stewart, 1991). 
 
Typically, single daily injections of 2-4mg/kg amphetamine result in 
behavioural sensitisation (Robinson & Kolb, 1999). More extreme 
exposures consisting of daily amphetamine administration in doses 
ranging from 5 to 32mg/kg (i.p.) produced behavioural tolerance (e.g. 
Demellweek & Goudie, 1983; Jackson, Bailey, Christie, Crisp, & 
Skerritt, 1981; Lewander, 1971; Robinson & Becker, 1982). It has been 
suggested that a critical factor is the interval between treatments rather 
than the dose (Robinson & Becker, 1986). Thus, relatively infrequent 
injections spaced up to a week apart may be more efficacious in 
producing sensitisation than injections given close together (Robinson, 
1984).  
 
The observation of sensitisation is also dependant on time since last 
exposure. Sensitisation was observed 3 days after an amphetamine pre-
treatment regime with the magnitude of the response increasing 5 and 
30 days post withdrawal (Kolta, Shreve, De Souza, & Uretsky, 1985). 
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Ideally, more than a day withdrawal following exposure is required as 
sensitisation has been observed 7, 14 and 28 days after the last dose but 
not after a single day withdrawal (Hitzemann, Tseng, Hitzemann, 
Sampath-Khanna, & Loh, 1977).  
 
Behavioural sensitisation is also dependent on the environmental 
context in which the drug is administered. Conditioned effects elicited 
by situational and environmental cues associated with the drug come to 
exert a powerful control over the manifestation of behavioural 
sensitisation. Typically, when examining environmental and contextual 
cues, the animals are taken from their home cages and moved to a 
novel test environment. Half of these, the paired group, are injected 
with a psychostimulant (drug paired with environment) and half with 
saline, the unpaired group. When removed from the test environment 
and placed back in their home cages the saline unpaired group receive 
the drug, thereby isolating the contextual environment from this group. 
On the test day, only the previously paired group showed a sensitised 
response (Pert, Post, & Weiss, 1990).  
 
A number of researchers have used similar methodology to examine the 
role of context in amphetamine produced sensitisation. Although 
context dependent sensitisation was blocked (Stewart & Druhan, 1993), 
and extinguished once gained (Stewart & Vezina, 1991),  the majority 
of reports confirm that environmental contextual cues are extremely 
important for the manifestation of behavioural sensitisation (Ahmed, 
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Stinus, Le Moal, & Cador, 1993; Badiani, Anagnostaras, & Robinson, 
1995; Badiani, Browman, & Robinson, 1995; Drew & Glick, 1988; 
Mazurski & Beninger, 1987; Stewart & Druhan, 1993; Vezina, 
Giovino, Wise, & Stewart, 1989).  
 
Sensitisation and Intravenous Self-Administration 
 
Investigators typically, and successfully, have measured the latency to 
acquisition of self administration showing drug pre-exposed animals 
acquiring self administration faster than drug naive animals (Horger, 
Giles, & Schenk, 1992; Horger, Shelton, & Schenk, 1990; Piazza, 
Deminiere, Le Moal, & Simon, 1989). Animals pre-exposed to a 
sensitising regimen of amphetamine were predisposed to-self 
administer amphetamine (Horger, Giles, & Schenk, 1992; D. Piazza, Le 
Moal & Simon, 1989) as indicated by decreased latency to acquire an 
operant response. However, pre-exposure to amphetamine decreased 
latency to acquisition of only low doses of drug ( Piazza, Deminiere, Le 
Moal, & Simon, 1989) using a low fixed ratio (FR) reinforcement 
schedule. When high doses of the drug were made available, under the 
same FR schedule, there was no difference between amphetamine and 
vehicle pre-exposed animals (Lorrain, Arnold, & Vezina, 2000) 
suggesting prior exposure may reduce the threshold reinforcing dose.  
 
When high doses of amphetamine were available in the self-
administration paradigm, amphetamine break point on a progressive 
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ratio (PR) schedule of reinforcement were higher for amphetamine pre-
exposed rats (Mendrek, et al., 1998; Vezina, Pierre & Lorrain, 1999). In 
the PR schedule, the number of lever responses required to obtain a 
reinforcer is increased for each successive reinforcer until a ‘break 
point’ that fails to support continued operant responding is reached. It 
has been suggested that increases in break point from drug pre-exposed 
animals reflects higher motivation to further seek the drug (Arnold & 
Roberts, 1997).  
 
Decreases in latency to acquisition and higher break points indicate 
pre-exposure to amphetamine enhances drug seeking as well as the 
acquisition rate of self-administration. One suggestion for this 
alteration has been linked to the sensitisation of mesolimbic dopamine 
neurons. Higher break points have been associated with increases in 
NAc DA (Vezina et al., 1999) as well as sensitisation to the locomotor 
activating effects of amphetamine (Mendrek, et al., 1998; Vezina et al., 
1999). 
 
Non-human primates, mice and rats will all self-administer MDMA 
(Banks, et al., 2007; Braida & Sala, 2002; Cornish, et al., 2003; 
Daniela, Brennan, Gittings, Hely, & Schenk, 2004; Daniela, Gittings, & 
Schenk, 2006; Fantegrossi, Ullrich, Rice, Woods, Winger, 2002; 
Fantegrossi, et al., 2004; Ratzenboeck, Saria, Kriechbaum, & Zernig, 
2001; Schenk, Gittings, Johnstone, & Daniela, 2003; Schenk, Hely, 
Gittings, Lake, & Daniela, 2008; Schenk, et al., 2007).  There have 
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however, been noted differences in latency to acquisition of MDMA 
self-administration when compared to other self-administered drugs. 
Acquisition of MDMA self-administration is relatively slow (Schenk et 
al., 2003) with more variability in the latency to acquisition compared 
with other self-administered drugs (e.g. Horger, et al., 1990; Horger, et 
al., 1992). 
 
These differences might be due to the different pharmacology of 
MDMA. It has been suggested that drugs with a greater effect on DA 
compared to 5-HT have a higher subjective reinforcement value (Wee, 
Anderson, Baumann, Rothman, Blough, & Woolverton, 2005) with  
reinforcing efficacy positively correlated with inhibition of dopamine 
reuptake (Ritz, Lamb, Goldberg, & Kuhar, 1988; Wilcox, Rowlett, 
Paul, Ordway, & Woolverton, 2000) and increases in extracellular DA 
(Self & Nestler, 1995). Moreover, it has been suggested that the ratio of 
DA to 5-HT is a better indicator of drug abuse potential than solely a 
positive correlation with DA reuptake inhibition or increased DA 
release. For example, when different equipotent DA releasers that 
differed in 5-HT release were self administered by rhesus monkeys, 
responding was lower when 5-HT potency was higher (Wee, et al., 
2005).  Further, Ritz and Kuhar (1989) reported a negative correlation 
between potency as a reinforcer and 5-HT transporter binding affinity. 
These data suggest that the ratio of 5-HT to DA is an important 
determinant of self administration. 
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Because of the predominant effect of MDMA on the serotonin system it 
has been suggested that the lower DA:5-HT ratio may explain the 
increased latency to acquisition of self-administration of MDMA 
(Schenk, et al., 2007). For example, acquisition to MDMA self 
administration for drug naive rats was produced in about 12 days 
(Schenk et al., 2003), whereas acquisition to cocaine self-
administration has been reported in as few as 5 days (Schenk & 
Partridge, 1997). With repeated administration of MDMA, there are 
long-term reductions in brain tissue concentrations of 5-HT and in 5-
HT reuptake sites (Ricaurte et al., 2000; Green et al., 2003; Gudelsky 
andYamamoto, 2003) thereby increasing the DA:5-HT  ratio. With 
continued  self-administration studies, further decreases in 5-HT would 
be produced and this might explain the development of MDMA as an 
efficacious reinforcer (Schenk, et al., 2007) . 
 
Initiation and Expression of Sensitisation 
 
Behavioural sensitisation is comprised of two distinct components, 1) 
initiation (also called ‘development’, ‘acquisition’ or ‘induction) and 2) 
expression. The initiation of sensitisation is the development of the 
augmented locomotor behaviour while the expression refers to the 
manifestation of that behaviour (Kalivas & Stewart, 1991; Pierce & 
Kalivas, 1997; Robinson & Becker, 1986; Stewart & Badiani, 1993).  
Effects on different components of the mesolimbic DA system have 
been attributed to these two processes.  
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DA in the ventral tegmental area VTA appears to be responsible for the 
induction of behavioural sensitisation following repeated amphetamine 
exposure (Nelson, Wetter, Milovanovic, & Wolf, 2007; Pierce & 
Kalivas, 1997; Vanderschuren & Kalivas, 2000; Vezina, 1996; Wolf & 
Xue, 1998). Direct infusion of DA antagonists into the VTA 
completely blocked the acute locomotor activating effects of 
amphetamine (Vezina & Stewart, 1989). Repeated amphetamine 
injections into the VTA induced behavioural sensitisation to either 
systemically, or intra NAc amphetamine (Bjijou, Stinus, Le Moal, & 
Cador, 1996; Cador, Bjijou, & Stinus, 1995; Hooks, Jones, Liem, & 
Justice Jr, 1992; Kalivas & Weber, 1988; Vezina & Stewart, 1989). In 
contrast, injections of amphetamine into other mesolimbic substrates 
did not result in sensitisation (Hitzemann, Wu, Hom, & Loh, 1980; 
Kalivas & Weber, 1988; Perugini & Vezina, 1994). It would appear 
that drug effects within the VTA underlie the induction of behavioural 
sensitisation.  
 
Acute administration of amphetamine increased DA overflow in the 
NAc (Carboni, Imperato, Perezzani, & Di Chiara, 1989; Kalivas & 
Stewart, 1991; Robinson & Berridge, 1993; Sharp, Zetterstrom, 
Ljungberg, & Ungerstedt, 1987), but repeated intra-NAc administration 
did not result in further increases in synaptic DA (Dougherty & 
Ellinwood, 1981). Intra-NAc amphetamine produced locomotor 
activity (Pierce & Kalivas, 1995), and repeated administration resulted 
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in sensitisation. However, there was no sensitised response to a further 
amphetamine challenge (Kalivas & Weber, 1988). Thus the pattern of 
responding to a sensitising regime of amphetamine differs when the 
drug is infused into the VTA or the NAc.  
 
A comparison of the effect of amphetamine administered into the VTA 
and NAc helps to clarify their role in induction and expression of 
amphetamine sensitisation. (Cador, et al., 1995). Amphetamine injected 
into the NAc dose-dependently increased locomotor activity but 
repeated exposure failed to produce behavioural sensitisation. Repeated 
injections into the VTA did not produce locomotor activity but resulted 
in locomotor activity following an intra-NAc amphetamine challenge. 
It was concluded that repeated amphetamine expose to the NAc was not 
responsible for the dopaminergic adaptations underlying behavioural 
sensitisation (Cador, et al., 1995) 
 
Role of Dopamine D1 and D2-like Receptors in Amphetamine Sensitisation 
 
In the 1970’s it was proposed that there were two classes of dopamine 
receptor, the D1 and D2 (Cools & Van Rossum, 1976; Kebabian & 
Calne, 1979). Around the 1990’s further heterogeneity revealed at least 
five subtypes of dopamine receptors (D1-D5) (Civelli, Bunzow, & 
Grandy, 1993; Sibley & Monsma, 1992). The five subtypes are now 
divided into two families and these are referred to as the D1-like (D1, 
D5) and the D2-like (D2, D3, D4) dopamine receptors. The most 
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notable distinguishing function of the two receptor subtypes is the 
effect on adenylyl cyclase with the D1-like increasing and the D2-like 
decreasing adenylyl cyclase activity or having no effect. A further 
difference is the presence (or otherwise) of an autoreceptor; with 
pharmacological studies indicating that the DA autoreceptor is of the 
D2 type (Nisoli, et al., 2009). DA D2 receptors function both as 
presynaptic autoreceptors and as postsynaptic receptors. Presynaptic 
autoreceptors modulate dopamine synthesis and release, and inhibit 
neuronal firing. 
 
Pre-treatment with the D1-like receptor antagonist, SCH23390, blocked 
the development of sensitisation produced by intra-VTA infusions of 
amphetamine (Vezina & Stewart, 1989). SCH23390 also blocked the 
development of sensitisation produced by repeated systemic injections 
of amphetamine (Stewart & Vezina, 1989). These finding implicated a 
critical role of D1-like receptors in the VTA in amphetamine 
sensitisation. However, an alternative explanation for the attenuation of 
sensitisation was raised. It was suggested that intra-VTA administration 
of the D1 like antagonist may have diffused into the entire brain (Di 
Chiara, 1993) explaining why subsequent administration of 
amphetamine had not produced a sensitised response. As a test of this 
hypothesis, intra-VTA amphetamine was co-administered with 
SCH23390, sulpiride (a selective D2 antagonist) or kitanserin (5-HT2 
antagonist). SCH23390, but not ketanserin or sulpiride, dose 
dependently blocked the induction of behavioural sensitisation. (Bjijou, 
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et al., 1996). Systemic administration of the D2 receptor antagonist, 
Ro22-2586, also failed to effect the development of sensitisation 
(Vezina & Stewart, 1989). As was found with sulpiride, intra-VTA 
administration of other D2 antagonists, spiperone or eticlopride, also 
failed to alter the induction of sensitisation to the locomotor activating 
effect of amphetamine (Bjijou, et al., 1996; Vezina, 1996). Thus DA 
D1-like, but not D2-like, receptors within the VTA appear critical to 
the initiation of sensitisation to amphetamine.  
 
Repeated amphetamine administration induced a subsensitivity of D2 
autoreceptors (Wolf, White, Nassar, Brooderson, & Khansa, 1993) 
which may, in part, explain the failure of the D2 antagonists to block 
the induction of sensitisation. These autoreceptors are impulse 
regulating on the pre-synaptic neuron and prolonged exposure to 
amphetamine reduced the responsiveness of the receptors thereby 
increasing DA synthesis and release. White and Wang (1984) showed 
that a relatively high daily dose of amphetamine (1 or 2 x 5mg/kg i.p. 
for 5 days) significantly reduced the ability of intravenous apomorphine 
(a non-selective DA agonist, having a slightly higher affinity for D2-
like dopamine receptors) to suppress dopamine firing in the VTA 
suggesting a subsensitivity of the D2 autoreceptor. With increases in 
dopamine release being induced through D2 autoreceptor subsensitivity, 
blocking the D2 receptor, as Vezina and Stewart (1989) and Bjijou and 
colleagues (1996) had done, would not be expected to block the process 
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of induction to amphetamine but rather augment the process 
(Vanderschuren, Schoffelmeer, Mulder, & De Vries, 1999).  
 
DA VTA autoreceptor subsensitivity is a transient alteration which 
does not persist during withdrawal from repeated amphetamine. 
Following repeated exposure to a low dose of amphetamine, and 3 days 
withdrawal, intra-VTA application of the D2 agonist, quinpirole, failed 
to reduce firing rates suggesting a subsensitivity of the autoreceptor. 
This decreased response, however, was no longer evident 14 days 
following treatment, even though behavioural sensitisation persisted 
(Wolf et al., 1993).  
 
MDMA and Locomotor Activity 
 
MDMA increases the release and prevents reuptake of DA. Following 
MDMA administration, increases in extracellular DA have been 
reported in striatum (Gudelsky & Yamamoto, 2008; Schmidt, Levin, & 
Lovenberg, 1987; Steele, Nichols, & Yim, 1987), nucleus accumbens 
(Bankson & Yamamoto, 2004; Cadoni, et al., 2005), prefrontal cortex 
(Nair & Gudelsky, 2004) and hippocampus (Shankaran & Gudelsky, 
1998).  
 
The mechanism of DA release is both transporter and impulse 
dependent with DAT inhibitors (Nash & Brodkin, 1991; Shankaran, 
Yamamoto, & Gudelsky, 1999) since the sodium channel blocker, 
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tertrodotoxin, (Yamamoto, Nash, & Gudelsky, 1995) attenuated 
release. MDMA induced locomotor activity was also attenuated by 
systemic administration of the D1 like antagonist, SCH23390, (Daniela 
et al., 2004) and  the D2 antagonist, eticlopride (Ball, Budreau & Rebec, 
2003).  
 
Although MDMA primarily promotes DA release via the transporter, 
the serotonin selective reuptake inhibitor (SSRI), fluoxetine, suppressed 
MDMA stimulated DA release suggesting a role of serotonergic 
mechanisms (Callaway, Wing, & Geyer, 1990).  Further, 5-HT2 
agonists potentiated (Gudelsky et al., 1994) and 5-HT2 antagonists 
suppressed (Nash, 1990; Schmidt et al., 1994; Yamamoto et al., 1995) 
the MDMA-induced DA increase. More specifically, the 5-HT2A 
receptors may modulate DA through increasing regulation of either DA 
synthesis or DA neuron firing rate (Schmidt et al. 1992; Gudelsky et al. 
1994). Indeed, basal firing rate of DA neurons were increased by 5-
HT2C receptor antagonists and inhibited by 5-HT2C receptor agonists 
(Di Matteo et al. 2000; Gobert et al. 2000) through a tonic inhibitory 
influence on release (Ball & Rebec, 2005). 
 
Because of the well documented role of DA in locomotor activity it is 
not surprising that both peripheral and central administration of 
MDMA increased locomotor activity. Gold and Koob (1988) were one 
of the first to demonstrate MDMA produced locomotor activity in rats 
and since then there have been a number of other reports (e.g. Bubar, 
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Pack, Frankel, & Cunningham, 2004; Yamamoto & Spanos, 1988). 
MDMA induced locomotor activity was decreased by systemic 
administration of the D1 like antagonist, SCH23390 (Daniela, et al., 
2004) and the D2 like antagonist, eticlopride (Ball, Budreau, & Rebec, 
2003).  Moreover, pharmacological blockade of the DAT inhibited 
MDMA induced locomotor activity (Callaway et al., 1990). The 
selective 5-HT2A antagonist MDL 100,907, also suppressed MDMA 
produced hyperactivity. Other less selective 5-HT2A antagonists 
(ritanserin, methiothepin, MDL 28,133A, SR46349 and clozapan) also 
reduced MDMA stimulated activity (Ball & Rebec, 2005; Kehne, et al., 
1996) but the 5-HT2C antagonist, SB242084, potentiated the locomotor 
stimulant effects of MDMA (Fletcher, Sinyard, & Higgins, 2006). It 
has been suggested that the 5-HT antagonists altered MDMA produced 
hyperactivity by modulating DA release (Ball & Rebec, 2005). 
 
Of interest, chronic treatment with DOI, although a 5-HT2A agonist, 
produced an inhibitory regulation of the 5-HT2C receptor, which 
increased MDMA produced locomotor activity. This was attributed to 
5-HT2A mechanisms because the response to the 5-HT2C receptor 
agonist, MK212, remained unaffected by repeated DOI pre-treatment. 
(Ross, Herin, Frankel, Thomas, & Cunningham, 2006). Indeed, 
repeated DOI treatment decreased 5-HT2A receptor protein expression 
in the PFC and shell of the NAc. Because 5-HT2A receptor activation 
increased DA release (Ball & Rebec, 2005), these findings suggest that 
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5-HT2A receptors in the DA terminal areas of the PFC and NAc might 
be critical to MDMA produced hyperactivity. 
 
MDMA and behavioural sensitisation 
 
Few studies have examined behavioural sensitisation to MDMA and fewer 
still have examined the mechanisms underlying the development or 
expression of sensitisation. Repeated intermittent administration of MDMA 
produced a progressive and enduring increase in the behavioural response 
to the drug. One of the early investigations into MDMA behavioural 
sensitisation was conducted by Spanos and Yamamoto (1989) who studied 
both the acute and chronic behavioural effects of MDMA. Acute effects 
showed a dose related increase in MDMA produced locomotor activity. 
Chronic exposure, consisting of alternate-day injections with locomotor 
challenge doses after the sixth and twelfth injections, produced a dose 
dependent increase in all behavioural measures. Furthermore, authors 
reported correlated extracellular in-vivo voltammetery measures of DA 
release paralleling the time course of MDMA induced hyperlocomotion. 
When examining the chronic behavioural effects of MDMA exposure 
Kalivas, Duffy and White (1998) concurred with Spanos and Yamamoto 
(1989), finding an augmented behavioural response to the drug. In addition, 
and paralleling amphetamine induced DA release, they found a dose 
dependent increase in extracellular DA in the nucleus accumbens 
suggesting there may be patterns of MDMA produced neuroadaptations 
that overlap with other commonly abused amphetamines. In corroboration 
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with this finding, MDMA induced increases in cell firing in the dorsal 
striatum were increased in sensitised rats (Ball et al., 2006). Serotonergic 
mechanisms might also be involved since the 5-HT1B/1D antagonist, 
GR127935, attenuated the development of sensitisation (McCreary et al., 
1999). However, Modi, Yang, Swann, & Dafn (2006) failed to find cross 
sensitisation to amphetamine and methylphenidate after repeated MDMA 
administration. Chronic administration produced sensitisation of only a 
transient nature evident on challenge day 13 but not on day 38. Chronic 
dosage of 5 mg/kg persisted for a longer period of time with motor indices 
of sensitisation still evident on day 38. The administration of 10.0 mg/kg 
MDMA however, produced increases in locomotor activity. This does not 
rule out the possibility of overlapping neural adaptations but may suggest 
those adaptations to be more akin to cocaine rather than amphetamine or 
methylphenidate. 
 
Intra-NAc core administration of the D1-like receptor antagonist, 
SCH23390, prevented the expression, but not the development, of 
behavioural sensitisation (Ramos, Goni-Allo, & Aguirre, 2004). 
Although Ramos et al. (2004) did not observe sensitised responding 
after SCH23390 D1 blockade through pre treatment with MDMA, D1 
receptor activation must still have occurred. The longer half life of 
MDMA versus SCH23390 would ensure D1 receptor activation past 
any evident time analysis of the 60 minute test for locomotion or post 
activity test chamber when the rats were placed back in their home 
cage. Indeed, the obvious interpretation is that made by the authors in 
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that the D1 receptor is not involved in the induction of sensitised 
responding. It was argued that projections from the prefrontal cortex 
(PFC) might mediate behavioural sensitisation to MDMA because 
ibotenic acid lesions of the dorsal medial PFC, that destroyed cell 
bodies, blocked both the induction and expression of sensitisation 
(Ramos, Goni-Allo, & Aguirre, 2005b). Dopaminergic mechanisms 
were implicated since administration of the D1 like receptor agonist, 
SCH23390, into the medial PFC blocked the expression of 
sensitisation. Because SCH23390 is also a 5-HT2C receptor agonist, this 
mechanism in the medial PFC might play a key role in behavioural 
sensitisation to MDMA. This idea was supported by the finding that 
attenuation of sensitisation produced by SCH23390 was reversed by 
administration of the 5-HT2C receptor antagonist, RS 102221 and 
sensitisation was produced by the 5-HT2C agonist MK212 (Ramos, 
Goni-Allo, & Aguirre, 2005a). These data support the idea that MDMA 
induced sensitisation was mediated by 5-HT2C receptor stimulation in 
the medial PFC and not by the blockade of medial PFC D1 receptors.  
 
The current investigation 
 
MDMA induces locomotor, as well as sensitised locomotor responding 
that can be attenuated through dopaminergic antagonists. Despite a 
plethora of evidence suggesting a crucial role of dopamine in 
behavioural sensitisation to psychostimulants, its role in MDMA 
sensitisation is yet to be fully investigated. It has been postulated that 
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activation of DA D1 receptors initiate the neural adaptations underlying 
amphetamine sensitisation (e.g. Stewart and Vezina 1989; Kalivas and 
Stewart 1991; Bjijou et al. 1996; Vezina 1996). DA D2 pre-synaptic 
receptors show evidence of transient sub-sensitivity (White and Wang 
(1984) while DA D2 post-synaptic receptors may become sensitised 
(Wolf et al., 1993). However, the role in MDMA induced sensitisation 
is less clear. One way to address this is through behavioural 
pharmacology.  
 
The following set of experiments aims to firstly determine parameters 
for the development of sensitisation to the locomotor activating effects 
of MDMA and it is hypothesised that repeated intermittent 
administration will produce an augmented locomotor activity in 
response to a further challenge dose of the drug. Secondly, the thesis 
will determine whether cross-sensitisation is produced to the locomotor 
activating effects of  D1-like and/or D2-like receptor agonists and 
antagonists. Thirdly, the relevance of sensitisation to drug self 
administration will be evaluated. Finally, because deficits in 5-HT have 
been reported following exposure to MDMA, HPLC analysis will be 
used. Tissue levels of 5-HT, DA and their primary metabolites will be 
measured to ascertain what changes in neurochemical levels result from 
repeated administration of MDMA. 
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Experiment 1: Induction and expression of behavioural 
sensitised responding to MDMA locomotor activating effects 
General methodology  
Subjects 
 
The subjects were male Sprague-Dawley rats, weighing between 250-350g 
(approximately 60 days old). The animals were bred at Victoria University in 
Wellington, New Zealand and were initially housed in pairs and then housed 
singly in a temperature- (21˚C) and humidity- (55%) controlled room. The 
colony was maintained on a 12-hr light/dark cycle with lights on at 0700. 
Food and water were available ad libitum except during testing periods. 
Laboratory animal care principles of the Victoria University of Wellington 
Animal Breeding Facility were followed, and the Victoria University of 
Wellington Animal Ethics Committee approved all protocols.  
Apparatus for locomotion studies 
 
Eight open field chambers (450mm x 450mm; Med Associates (ENV-
515) Vermont, USA) equipped with four banks of 16 photocells on each 
of the internal walls of the chamber were used to measure horizontal 
locomotion. Photocells were set at 25mm above the floor of the chamber 
and spaced evenly at 25mm centres around the periphery.  
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The open field boxes were interfaced with a computer and data were 
obtained using Med Associates software. Each activity chamber was 
enclosed in sound attenuating boxes (Med associates; Vermont USA). A 
beam ‘box’ was pre-set encompassing a 3 x 3 beam square (50mm x 
50mm).  Movement outside of this ‘box’ broke the beams and constituted 
one locomotor count.  
 
All testing was conducted during the light cycle. A red house light was 
illuminated during testing and white noise was also continually present to 
mask extraneous disturbances. Prior to and after each locomotor activity test, 
the chamber interiors were cleaned and wiped with Virkon ‘S’ disinfectant 
(Southern Veterinary Supplies, NZ).  
Drugs: 
• Racemic MDMA hydrochloride, (ESR Ltd, Porirua, New Zealand). 
• d-Amphetamine, (SIGMA; Australia).  
• SCH23390 Hydrochloride, [R(+)-7-Chloro-8-hydroxy-3-methyl-1-
phenyl-2,3,4,5-tetrahydro-1H-3-benzazepine hydrochloride], (Tocris 
Bioscience, Natick, Massachusetts). 
• SKF81297 hydrobromide, [R-(+)-6-chloro-7,8-dihydroxy-1-phenyl-
2,3,4,5-tetrahydro-1-H-3-benzazepine hydrochloride], (Tocris Bioscience, 
Natick, Massachusetts). 
• Apomorphine hydrochloride, [R-5,6,6a,7-tetrahydro-6-methyl-4H-
dibenzo[de,g]quinoline-10,11-diol hydrochloride],  (Tocris Bioscience, 
Natick, Massachusetts). 
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• Eticlopride, [S(-)-3-Chloro-5-ethyl-N-[(1-ethyl-2-pyrrolidinyl)methyl]-6-
hydroxy-2-methoxybenzamide hydrochloride], (SIGMA; Australia).  
All the above drugs were dissolved in sterile saline (0.9%NACL).  
• RS102221, [8-[5-(2,4-Dimethoxy-5-(4-
trifluromethylphenylsulfonamido)phenyl-5-oxopentyl]-1,3,8-
triazaspiro[4,5]decane-2,4-dione hydrochloride], (Tocris Bioscience, 
Natick, Massachusetts). 
 
All the above drugs were dissolved in sterile saline (0.9%NACL) 
apart from RS102221 which was suspended in a solution of 1% polysorbate 
80 (Tween® 80). 
Subcutaneous (SC) or Intraperitoneal (IP) injections were in a volume of 1 
ml/kg. All drug doses refer to the salt. 
 
General Sensitisation Protocol  
 
Rats were housed individually and were weighed and handled daily, one 
week prior to the commencement of all experiments. 
 
Days 1-5: 
Rats were transported daily from their home cages to the locomotor 
activity room and placed into the middle of the open field chambers. 
Locomotor activity was recorded for 15 or 30 minutes, recording was 
then paused while rats were administered drug or saline and activity was 
recorded for an additional 60 minutes. Activity data were collected at 5 
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min intervals during the 30 min pretreatment and 60 min post-treatment 
periods.  
 
Days 6 & 7: 
For the majority of experiments, there was a two day withdrawal period 
during which the rats remained in the home cages. A number of 
experiments had extended withdrawal periods (see table 1) in which the 
rats remained in their home cages. 
 
Day 8: 
Rats were transported from their home cages to the locomotor activity 
room and placed into individual activity chambers. Activity was recorded 
during a 15 or 30 minute pretreatment and 60 minute post-treatment 
period. 
Data Analysis  
 
Data analyses (unless otherwise specified) were conducted on the activity 
counts during the post injection interval. Locomotor responses were 
analysed using a 1, 2 or 3-way (as specified in each results section) 
repeated measures Analysis of Variance (ANOVA) with the repeated 
measure of time. 
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Overall layout for experiment 1A and 1B  
            Table 1. 
Pre-treatment  
Exp. 1A Exp. 1B 
 Amphetamine 
(2.0mg/kg) 
Vehicle  MDMA 
(5.0mg/kg) 
Vehicle  MDMA 
(10.0mg/kg) 
Vehicle 
Day 1 vs. 
day 5 Yes  Yes  Yes  Yes Yes Yes 
2-day 
Withdrawal Yes  Yes  Yes  Yes Yes Yes 
9-day 
withdrawal No No No No Yes Yes 
28-day 
withdrawal Yes  Yes  No No Yes Yes 
 
Table 1. Within experiment 1, drug pre-treatment and withdrawal periods 
vary. The table identifies the drug pre-treatment administered and withdrawal 
period used. 
 
 
 
Experiment 1a Amphetamine-produced sensitisation  
Background 
 
Repeated intermittent exposure to a number of stimulant drugs produces a 
sensitised locomotor response. The sensitised behavioural responses 
reflect a host of neuroadaptations. These complex changes are greatly 
impacted upon by a number of parameters in the drug administration 
regimen including withdrawal time from the last drug administration 
(Kolta, et al., 1985) dose ( Kalivas & Duffy, 1993; Paulson, Camp, & 
Robinson, 1991; Paulson & Robinson, 1995), drug exposure duration 
(Robinson & Becker,1986), and the context in which the drug is delivered 
(Badiani, Browman, et al., 1995; Badiani, Camp, & Robinson, 1997; 
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Robinson, Browman, Crombag, & Badiani, 1998; Stewart & Badiani, 
1993). 
 
To this end Experiment 1 as a whole was designed to determine the 
protocols required to induce reliable sensitisation to the locomotor 
activating effects of MDMA. To start, experiment 1 reproduced 
amphetamine sensitisation and then used the delivery and withdrawal 
protocols to attempt to induce MDMA sensitisation. Different doses of 
MDMA were used in the pre-treatment regimen, and following drug 
abstinence, varying challenge doses were administered in order to 
determine whether there were changes in the dose response function. 
Because MDMA is an amphetamine derivative, it was hypothesised that 
the induction and expression protocols for sensitisation to the behavioural 
effects of amphetamine and MDMA would be similar.  
 
Experiment 1a Procedure 
 
On days 1-5, rats (numbers vary and are reported in each experiment) 
were given a single daily administration of amphetamine (0.0 or 2.0 
mg/kg, IP). This dose and injection regimen has been shown to produce 
persistent sensitisation to the locomotor stimulant effects of amphetamine 
(Vanderschuren, Schmidt, et al., 1999) and has been used in a number of 
previous investigations (Laudrup & Wallace, 1999; McNamara, 
Davidson, & Schenk, 1993; Nordquist, et al., 2008). 
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After either 2 or 28 days of withdrawal, during which all rats were left in 
home cages, the locomotor  activating effects of  amphetamine (0.0 or 0.5 
mg/kg, IP) were measured as described above. 
 
Experiment 1a Results. 
 
Amphetamine pre-treatment day 1 vs. day 5 
 
Figure 1.1 shows locomotor activity as a function of time on Days 1 and 
5 of the pre-treatment regimen. A mixed 3-way ANOVA [Day (1 & 5) x 
Drug (amph or vehicle) X Time (12 five min bins)] on the counts post 
injection (‘time 0’) revealed a significant main effect of Day (F(1,22) = 
21.65, p< 0.05),  Drug (F(1,22) = 219.74, p< 0.05) and a significant 
interaction between Day and Drug (F(1,22) = 14.98, p< 0.05). There was 
also a 3 way interaction for Day x Drug x Time (F(11,242) = 2.46, p< 
0.05).  A post hoc analysis of the amphetamine data (Day x Time) showed 
that locomotor activity counts were higher on day 5 compared to day 1 of 
testing (F(1,22) = 18.95, p< 0.05). 
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Figure 1.1.  Locomotor counts for the 75 minutes of testing across days. 
Rats were administered either amphetamine (2.0mg/kg i.p.) (n=12) or 
vehicle (n=12) each day in the testing chamber. Locomotor counts are 
summed into bins of 5 minute intervals with time ‘0’ being the time of 
drug injection.  
 
Amphetamine pre-treatment 2-day withdrawal 
 
Figure 1.2 shows locomotor activity as a function of time on challenge 
day (day 8). A mixed 3-way ANOVA [pre-treatment (amph or vehicle) x 
Dose (0.0 or 0.5mg/kg) x time (12 five min bins)] revealed a significant 
effect of pre-treatment (F(1,82) = 3.99, p< 0.05), and Dose (F(1,82) = 
11.56, p< 0.05), but no interaction between pre-treatment and Dose 
(F(1,82) = 1.04, ns). 
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Figure 1.2.  Locomotor counts for the 75 minutes of testing following 
injection of either amphetamine (0.5mg/kg i.p.) or vehicle. Data were 
collected  following 2 days withdrawal. The first listing in the legend 
identifies the group’s pre-treatment drug while the second indicates the 
challenge drug. Sample sizes are in brackets beside the listings. 
Locomotor counts are summed into bins of 5 minute intervals with time 
‘0’ being the time of drug injection. 
 
Group differences were examined with a 1-way ANOVA (Veh-Amph, 
Amph-Amph,) on post injection totals.  An overall difference between the 
groups was found (F(1,49) =  4.18,  p< 0.05). Whereas the low dose of 
amphetamine failed to produce significant locomotor activation in the 
vehicle pre-treated rats, increased activity was produced in the 
amphetamine pre-treated rats during the initial 30 minute post injection 
period. When total locomotion for just the initial post injection 30 minute 
period was compared activity in the Amph-Amph group was significantly 
higher than activity of all other groups (p<0.05). 
 
(26) 
(25) 
(17) 
(18) 
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Amphetamine pre-treatment 28-day withdrawal 
 
A further group of vehicle (n=7) and amphetamine (n=7) pre-treated rats 
were administered 0.5 mg/kg i.p. amphetamine 28 days following the 
sensitisation regimen. Figure 1.3 shows the time course for the total 75 
minutes following amphetamine (0.5mg/kg i.p.) administration. 
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Figure 1.3.  Locomotor counts for the 75 minutes of testing following 28 
days withdrawal. All animals were challenged with amphetamine 
(0.5mg/kg i.p.) with the legend indicating vehicle and amphetamine pre-
treated rats. Locomotor counts are summed into bins of 5 minute intervals 
with time ‘0’ being the time of drug injection 
. 
 
 
The amphetamine pre-treated rats tended to be more responsive to the 
effect of amphetamine but the effects were of much smaller magnitude 
than when testing was conducted following 2 days withdrawal (Figure 
1.2). Additionally, amphetamine pre-treated rats tended to have higher 
activity scores during the pre-treatment phase of testing although 
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variability throughout testing was high. A repeated measures ANOVA 
(pre-treatment x time) failed to reveal any significant differences between 
the two groups over the 30 minutes post injection (F(1,6) = 1.085, p> 
0.05) or the 60 min post injection period (F(1,12) = 1.247, p> 0.05). 
 
Experiment 1b, MDMA-Produced Sensitisation   
Procedure 
 
On days 1-5, rats were given a single daily administration of MDMA 
(0.0, 5.0 or 10.0 mg/kg i.p.) and activity was measured. These doses were 
chosen based on previous literature that has demonstrated sensitisation 
(Ramos, et al., 2005a; Spanos & Yamamoto, 1989). After 2, 9 or 28 days 
of withdrawal, during which all animals remained in their home cages, 
locomotor activating effects of MDMA (0.0, 2.5, 5.0 & 10.0 mg/kg i.p.) 
were measured as above.  (28 day withdrawal animals were housed in 
pairs during the 28 day drug abstinence period). 
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Experiment 1b Results. 
 
5.0 mg/kg MDMA pre-treatment day 1 vs. day 5 
 
During initial tests, a large sample of rats were administered repeated 
intermittent administration of the lower (5.0 mg/kg, IP) dose of MDMA. 
The locomotor activating effects of MDMA as a function of time on Days 
1 and 5 of treatment are presented in Figure 1.4. MDMA produced 
hyperactivity (F(1,84) = 83.24, p< 0.05) was not substantially altered by 
repeated exposure and the ANOVA failed to reveal significant effects of 
Day (F(1, 84) = 2.2, ns) or an interaction between Day and Drug (F(1, 84) 
= 3.21, ns).  
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Figure 1.4.  Average locomotor counts for the 90 minutes of testing on 
day 1 and 5 following administration of MDMA (5.0mg/kg i.p.) (n=43) 
or vehicle (n=43) in the test boxes. Locomotor counts are summed into 
bins of 5 minute intervals with time ‘0’ being the time of drug injection.  
 
 
 
 
5.0 mg/kg MDMA pre-treatment 2-day withdrawal 
 
 
Following a two day withdrawal the motor activating effects of various 
doses of MDMA (0.0, 2.5, 5.0 10.0 mg/kg) were measured. Figure 1.5 
shows the time course data.  
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Figure 1.5.  Locomotor activating effects of various doses of MDMA 
following a 2-day withdrawal from daily administration of MDMA 
(5.0mg/kg i.p.) or vehicle. Top panel is the time course of locomotor 
activity for vehicle pre-treated rats. Bottom panel is the time course of 
locomotor activity for MDMA pre-treated rats. Locomotor counts are 
summed into bins of 5 minute intervals with time ‘0’ being the time of 
drug injection 
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A mixed 3-way ANOVA [Pre-treatment (MDMA or vehicle) x Dose (0.0, 
2.5, 5.0, 10.0) x time (12 five min bins)] revealed a main effect of Pre-
treatment (F(1,79) = 4.08, p<0.05) and Dose (F(3,79) = 23.73, p<0.05) 
but no significant interaction between Pre-treatment and Dose (F(3, 79) = 
0.44, ns).   
 
Figure 1.6 presents the total activity data collapsed across time following 
each dose of MDMA for the MDMA and vehicle pre-treatment groups. 
 
0
2000
4000
6000
8000
10000
12000
14000
16000
18000
0 2.5 5 10
Challenge dose MDMA (mg/kg) 
To
ta
l A
ct
iv
ity
 
Co
u
n
ts
Vehicle pre-treat
MDMA Pre-treat (5.0 mg/kg)
 
Figure 1.6.  Total locomotor counts on challenge day for the 60 minutes 
post injection with vehicle and MDMA (5.0 mg/kg i.p.) pre-treated rats. 
After two days of withdrawal rats were challenged with MDMA (0.0, 2.5, 
5.0 or 10.0mg/kg i.p.). * difference from vehicle pre-treated group. 
 
Analysis on total locomotor activity counts during the 60 minutes post-
injection period was conducted using a 2-way ANOVA (Pre-treatment x 
Dose).  Main effects were echoed from the repeated measures analysis 
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(7) 
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(17) (15) 
(8) 
(8) 
* 
* 
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above [a main effect for Pre-treatment (F(1,79) = 4.08, p<0.05) and Dose 
(F(3,79)=23.73, p<0.05)]. Independent samples t-tests revealed MDMA 
pre-treated rats were more responsive to the 0.0 mg/kg (t(22) = -2.04, p< 
0.05) and the 2.5 mg/kg (t(6.396) = -2.57, p< 0.05) doses (Levene’s test 
for equal variances violated, adjusted df reported). 
 
10.0 mg/kg MDMA pre-treatment day 1 vs. day 5 
 
 
Figure 1.7 shows MDMA-produced hyperactivity on Days 1 and 5 of the 
higher dose pre-treatment regimen (0.0 (n=19) or 10.0 (n=21) mg/kg i.p.) 
A mixed 3-way ANOVA [Day (1 & 5) x Drug (MDMA or vehicle) X 
Time (12 five min bins)] on the post injection (‘time 0’) data revealed a 
main effect of Drug (F(1,38) = 284.57, p< 0.05), Day (F(1,38) = 4.87, 
p<0.05) and an interaction (F(1,38) = 7.86, p<0.05).  There was also a 3 
way interaction for Day x Drug x Time (F(11,418) = 4.43, p< 0.05). Post 
hoc analysis on the MDMA data (Day x Time) showed that MDMA-
produced hyperactivity was greater on Day 5 compared to Day 1 of 
treatment (F(1,36) = 5.16, p< 0.05). 
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Figure 1.7 Average locomotor counts for the 90 minutes of testing across 
days. Rats were administered either MDMA (10.0mg/kg i.p.) (n=21) or 
vehicle (n=19) each day in the test chambers. Locomotor counts are 
summed into bins of 5 minute intervals with time ‘0’ being the time of 
drug injection.  
 
 
 
 
10.0 mg/kg MDMA pre-treatment 2-day withdrawal 
 
 
Following a two day withdrawal locomotor activating effects of various 
doses of MDMA (0.0, 2.5, 5.0 10.0 mg/kg) were measured. Figure 1.8 
below presents the time course data.  
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Figure 1.8.  Locomotor activating effects of various doses of MDMA 
following a 2-day withdrawal from daily administration of MDMA 
(10.0mg/kg i.p.) or vehicle. Top panel is the time course of locomotor 
activity for vehicle pre-treated rats. Bottom panel is the time course of 
locomotor activity for MDMA pre-treated rats. Locomotor counts are 
summed into bins of 5 minute intervals with time ‘0’ being the time of 
drug injection 
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A repeated measures ANOVA [pre-treatment (MDMA or vehicle) x Dose 
(0.0, 2.5, 5.0, 10.0) x time (12 five min bins)] revealed a main effect of 
Pre-treatment (F(1,60)=15.841, p<0.05) and Dose (F(3,60)=35.71, 
p<0.05) but no significant interaction between Pre-treatment and Dose 
(F(3, 60) = 1.46, ns).   
 
Figure 1.9 presents the total activity data collapsed across time following 
each dose of MDMA for the MDMA and vehicle pre-treatment groups. 
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Figure 1.9.  Total locomotor counts on challenge day for the 60 minutes post 
injection with vehicle and MDMA (10.0 mg/kg i.p.) pre-treated rats. After 
two days of withdrawal rats were challenged with MDMA (0.0, 2.5, 5.0 or 
10.0mg/kg i.p.).  Numbers in brackets above each column is the sample size. 
* difference from vehicle pre-treated group 
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Analysis on total locomotor activity counts was conducted by using a 2-
way ANOVA (Pre-treatment x Dose). Post hoc t-tests revealed an 
increase in the activating effect of all doses of MDMA (p<0.05) accepting 
the 10.0 mg/kg challenge dose.  
 
10.0 mg/kg MDMA pre-treatment and 9 day withdrawal 
 
Figure 1.20 shows the time course of MDMA-produced hyperactivity 
(0.0 or 5.0 mg/kg, IP) for rats that had been pre-treated with the higher 
dose of MDMA (0.0 or 10.0 mg/kg, IP) 9 days earlier.   
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Figure 1.20. Locomotor activating effects of MDMA (0.0 or 5.0mg/kg 
i.p.) following a 9-day withdrawal from daily administration of MDMA 
(10.0mg/kg i.p.) or vehicle. The first listing in the legend identifies the 
group’s pre-treatment drug while the second indicates the challenge drug. 
Sample sizes are in brackets beside the listings. Locomotor counts are 
summed into bins of 5 minute intervals with time ‘0’ being the time of 
drug injection. 
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A repeated measures 3-way ANOVA [pre-treatment (MDMA or vehicle) 
x challenge (MDMA or vehicle) x time (12 five min bins)] failed to reveal 
a significant effect of pre-treatment (F(1,17) = 2.59, ns), or, perhaps due 
to the small sample sizes , an interaction between pre-treatment and 
challenge (F(1,17) = 2.60, ns). However, there was a main effect of 
Challenge (F(1,17) = 5.66, p<0.05).  
 
Figure 1.21 shows the time course of MDMA-produced hyperactivity 
(0.0 or 10.0 mg/kg, IP) for rats that had been pre-treated with MDMA 
(0.0 or 10.0 mg/kg, IP) 9 days earlier.  
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Figure 1.21. Locomotor activating effects of MDMA (0.0 or 10.0mg/kg 
i.p.) following a 9-day withdrawal from daily administration of MDMA 
(10.0mg/kg i.p.) or vehicle. The first listing in the legend identifies the 
group’s pre-treatment drug while the second indicates the challenge drug. 
Sample sizes are in brackets beside the listings. Locomotor counts are 
summed into bins of 5 minute intervals with time ‘0’ being the time of 
drug injection. 
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A repeated measures 3-way ANOVA [pre-treatment (MDMA or vehicle) 
x challenge (MDMA or vehicle) x time (12 five min bins)] failed to reveal 
a significant effect of pre-treatment (F(1,29) = 2.097, ns), or an 
interaction between pre-treatment and challenge (F(1,29) = 1.26, ns), but 
a main effect for challenge (F(1,29) = 93.39, p< 0.05).  
 
Figure 1.22 presents the total post-injection activity data collapsed across 
time following 9 days withdrawal for the MDMA and vehicle pre-
treatment groups. 
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Figure 1.22. Total post injection locomotor counts on challenge day for 
the 60 minutes post injection with vehicle and MDMA (10.0 mg/kg i.p.) 
pre-treated rats. After nine days of withdrawal rats were challenged 
with MDMA (0.0, 5.0 or 10.0mg/kg i.p.).  Numbers in brackets above 
each column is the sample size. * difference from vehicle pre-treated 
group 
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Analysis on total locomotor activity counts was conducted by using a 2-
way ANOVA (Pre-treatment x Dose). There were main effects for both 
pre-treatment (F(1,49) = 5.39, p< 0.05) and dose (F(2,49) = 32.48, p< 
0.05). Post hoc contrasts revealed an increase in the activating effect of 
both the 5.0mg/kg MDMA and 10.0 mg/kg MDMA challenge dose 
(p<0.05).  
 
10.0 mg/kg MDMA pre-treatment and 28 day withdrawal 
 
Figure 1.23 shows the time course of rats challenged with MDMA (5.0 & 
10.0mg/kg i.p.) following the 28 day withdrawal period from the MDMA 
(10.0mg/kg) pre-treatment  
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Figure 1.23. Locomotor activating effects of MDMA (5.0 or 10.0mg/kg 
i.p.) following a 28-day withdrawal from daily administration of MDMA 
(10.0mg/kg i.p.) or vehicle. The first listing in the legend identifies the 
group’s pre-treatment drug while the second indicates the challenge drug. 
Sample sizes are in brackets beside the listings. Locomotor counts are 
summed into bins of 5 minute intervals with time ‘0’ being the time of 
drug injection. 
 
 
A repeated measures 3-way ANOVA [pre-treatment (MDMA or vehicle) 
x Dose (5.0 & 10.0 MDMA) x time (12 five min bins)] revealed a 
significant effect of pre-treatment (F(1,41) = 4.97, p< 0.05), in addition to 
a main effect of Dose (F(1,41) = 25.53, p< 0.05), but no interaction 
between pre-treatment and Dose (F(1,41) = 1.04, ns). 
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Figure 1.24 presents the total post-injection activity data collapsed across 
time following 28 days withdrawal for the MDMA and vehicle pre-
treatment groups. 
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Figure 1.24. Total post injection locomotor counts on challenge day for 
the 60 minutes post injection with vehicle and MDMA (10.0 mg/kg i.p.) 
pre-treated rats. After 28 days of withdrawal rats were challenged with 
MDMA (5.0 or 10.0mg/kg i.p.).  Numbers in brackets above each column 
are the sample sizes. * difference from vehicle pre-treated group 
 
 
 
Analysis on total locomotor activity counts was conducted by using a 2-
way ANOVA (Pre-treatment x Dose) revealing both a Dose (F(1,41) = 
4.97, p< 0.05) and Pre-treatment (F(1,41) = 4.97, p< 0.05) main effect. 
Post hoc contrasts revealed an increase in the activating effect of the 5.0 
mg/kg MDMA challenge dose (p<0.05) but no difference in the 
10.0mg/kg MDMA challenge dose. 
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Experiment 1 Discussion 
 
This experiment was designed to develop protocols for sensitisation to the 
locomotor activating effects of MDMA. Repeated intermittent 
administration of both amphetamine and MDMA produced sensitised 
hyperactivity. This sensitised response was apparent during the pre-
treatment regimen and also following a 2 and 9-day withdrawal period for 
the MDMA pre-treated rats. 
 
Amphetamine-induced locomotor activity increased markedly from day 1 
to day 5. Following a 2-day withdrawal period, the response to a low dose 
of amphetamine was also enhanced. Additional tests were conducted to 
examine the persistence of the sensitised response however an 
amphetamine-produced sensitised response was no longer apparent 
following a 28 day withdrawal period. Although, 4 of the 7 amphetamine 
pre-treated animals had total post-injection locomotor counts approaching 
twice that of the average vehicle pre-treated group but variability was 
large and, as a group, it was not statistically reliable 
 
This finding is in contrast to other studies that have demonstrated an 
increase in the sensitised response following an extended withdrawal 
period of 28 days (Hitzemann , Tseng, Hitzemann, Sampath-Khanna & 
Loh, 1977; Paulson & Robinson,1995, 1996). It is possible that a 
different pre-treatment regimen may have resulted in a more persistent 
sensitised response in the above studies. However, under the current 
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conditions, sensitisation to the locomotor activating effects of 
amphetamine was observed 3, but not 28 days, following exposure. 
 
In contrast to the effects of repeated exposure to amphetamine, MDMA-
produced hyperactivity following the low dose (5mg/kg) failed to 
increase between days 1 and 5 of exposure. This result concurs with other 
findings (Ball, Budreau, & Rebec, 2006). Higher dose exposures 
however, showed an increase in MDMA produced activity from days 1-5 
of exposure.  
 
Following exposure to repeated doses of 5.0 mg/kg MDMA, a sensitised 
response to the effects of the lower dose of 2.5 mg/kg was observed. 
Repeated exposure to the higher dose of 10.0mg/kg MDMA increased 
locomotor activity between days 1 and 5 and following two days of 
withdrawal a sensitised response was observed to two lower doses (2.5 
and 5.0 mg/kg) of MDMA. Thus, the dose-effect curve for MDMA-
produced hyperactivity was shifted leftwards following both pre-
treatment regimens. Two other investigations have shown sensitisation 
following a similar MDMA pre-treatment regimen. In one, rats were 
treated for six consecutive days with 10.0 mg/kg MDMA, and tested with 
the same dose of MDMA following a 5-day withdrawal period (Modi, 
Yang, Swann, & Dafny, 2006). In the other, rats were treated for 5 days 
with a single dose of 10.0mg/kg per day followed by a 2 day withdrawal 
period (Colussi-Mas & Schenk, 2008). In both investigations 10.0 mg/kg 
pre-treatment produced a robust increase in MDMA-produced 
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hyperactivity across days during the pre-treatment period. The current 
investigation, in conjunction with the above data, suggests that a single, 
daily administration of the 10.0mg/kg pre-treatment dose compared to 
that of the 5mg/kg is the more effective pre-treatment dose during a 5-day 
exposure period to observe sensitisation. 
 
The present results suggest that a short withdrawal period enhances the 
manifestation of MDMA- induced behavioural sensitisation. The majority 
of investigations into MDMA sensitisation have also imposed a relatively 
short withdrawal period ranging from 48 hours to 12 days (Kalivas, et al., 
1998; McCreary, Bankson, & Cunningham, 1999; Ramos, et al., 2004; 
Spanos & Yamamoto, 1989). Consistent with these findings is the current 
data that show after 9 days withdrawal form repeated exposure to 
10.0mg/kg MDMA there was a sensitised response.  
 
Following longer withdrawal period of 28 days, however, sensitisation 
was no longer apparent. Instead, when compared to controls, the 
hyperactive response to 5.0 mg/kg MDMA - was decreased. This finding 
contrasts with a study that demonstrated sensitisation when testing was 
conducted following a 38 day withdrawal period (Modi, et al., 2006). The 
current results however, should be interpreted cautiously as the total 
locomotor activity counts in the saline control rats were extremely high. 
However, the locomotor counts for the MDMA pre-treated animals are 
comparable to the locomotor counts observed after 2 days (Figure 1.9) 
and 9 days (figure 1.22) withdrawal. One possible reason for the 
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increased response in vehicle rats is that during the 28 day withdrawal 
period rats were housed in pairs rather than singly as in the other groups. 
Housing environment is known to alter subsequent drug responses and 
animals housed in groups were more sensitive to amphetamine induced 
locomotor activity (Schaefer & Michael, 1991). If this is also true for 
MDMA produced hyperactivity the data suggest a differential influence 
of prior drug exposure. 
 
Of interest, there was a greater response in locomotor activity following 
administration of vehicle to the MDMA pre-treated rats. This conditioned 
effect has also been demonstrated following repeated administration of 
amphetamine (Anagnostaras & Robinson, 1996; Drew & Glick, 1988; 
Mazurski & Beninger, 1987; Vezina, et al., 1989). Although not 
specifically tested for, the current results suggest a role of context in the 
expression of MDMA-induced locomotor sensitisation. 
Summary experiment 1 
 
A sensitisation protocol was developed to induce sensitised responding to 
MDMA. An augmented locomotor response was evident across days of 
pre-treatment (day 1 vs. 5) and also evident with withdrawal periods of 
up to 9 days after the last exposure. Repeated administrations of either 
10.0 or 5.0 mg/kg for 5 days showed sensitised locomotor responding to a 
lower dose of the drug, however, the regimen of 5 daily treatments of 
10.0mg/kg produces persistent sensitisation.  
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Experiment 2: Changes in sensitivity of the D1 and D2 receptor to 
repeated intermittent exposure of MDMA 
Background 
 
An important mechanism underlying amphetamine produced hyperactivity is 
an increase in extracellular levels of DA in cell bodies and terminal regions 
of the mesolimbic system. Repeated intermittent administration of 
amphetamine increases the dopamine response and this sensitised 
neurochemical response is believed to result in behavioural sensitisation. The 
expression of sensitisation is typically measured as an increase in drug 
produced hyperactivity that can be explored with pharmacological 
manipulation of dopamine release, through for example, receptor activation 
or suppression. 
 
The role of the D1 and D2 receptors in amphetamine sensitisation has 
previously been investigated. Sensitisation was blocked by the D1-like 
antagonist, SCH23390 (Drew & Glick, 1990; Vezina & Stewart, 1989; 
Vezina, 1996) and sensitised locomotor activation was observed in response 
to the selective D1 dopamine receptor agonist, SKF81297, in amphetamine 
pre-treated rats (Chen et al., 2003). Intra VTA pre-exposure to the D2 
antagonist, eticlopride, blocked amphetamine produced locomotor activity 
(Tanabe, Suto, Creekmore, Steinmiller, Vezina, 2004) but effects of  the 
mixed D1/D2 agonist, apomorphine, has been equivocal. Following 
amphetamine-produced sensitisation, sensitisation to apomorphine-produced 
 69 
stereotypy was observed (Kuczenski & Segal, 1999) but this pre-treatment 
regimen failed to increase apomorphine-produced horizontal activity 
(Vanderschuren et al., 1999).  
  
Blockade of dopamine D1 like and D2 –like receptors significantly attenuated 
MDMA-induced locomotor activity in rats (Ball et al., 2003; Daniela et al., 
2004). A role of dopamine receptors in both the initiation and expression of 
sensitisation has been suggested (Ramos et al., 2004; 2005a; 2005b). Cross 
sensitisation to amphetamine has also been demonstrated suggesting common 
neural adaptations mediating behavioural sensitisation (Modi et al., 2006).  
 
To date, the role of the D1 and D2 receptors in the expression of sensitisation 
to the behavioural effects of MDMA has not been comprehensively 
examined. The current investigation aims to identify potential changes in D1 
and D2 receptor sensitivity as a result of repeated intermittent exposure to 
MDMA. It is hypothesised that the DA D1 and D2 receptors will be sensitised 
following a regimen of repeated intermittent MDMA administration. The 
response to the selective D1-like agonist, SKF81297, and the D1/D2 agonist, 
apomorphine will be determined in MDMA sensitised rats. Additionally, the 
potency of selective antagonists to attenuate MDMA produced hyperactivity 
will also be measured.  
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Experiment 2a method 
Experiment 2 follows the previously described general sensitisation 
methodology of five, single daily injections of MDMA (10.0mg/kg) followed 
by 2 days withdrawal.  
 
The ranges of doses chosen for SCH23390 have been shown to attenuate 
MDMA produced hyperlocomotion (Daniela et al., 2004). The dose range of 
eticlopride was based on Ball et al. (2003) demonstration of the attenuation 
of MDMA produced hyperactivity. Doses of the D1 selective agonist, 
SKF81297, were based on Reavill, Bond, Overend, & Hunter, (1993) and 
doses of apomorphine were chosen based on previous amphetamine 
sensitisation studies (Kuczenski & Segal, 1999; Vanderschuren, Beemster, & 
Schoffelmeer, 2003; Võikar, et al., 1999). The doses for the selective 5-HT2C 
antagonist, RS102221, were based on Bonhaus, et al., (1997). 
Experiment 2a Results. 
Effects of SKF81297 in MDMA sensitised rats 
 
Figure 2.1 shows the time course of the effects of SKF81297 in vehicle and 
MDMA pre-treated rats. A three-way ANOVA [Pre-treatment (10.0 MDMA 
or vehicle) X Dose (0.0, 0.5, 1.0, 2.0, 4.0 and 8.0) X Time (12 five minute 
bins)] was conducted. There was a main effect of Pre-treatment (F(1,72) = 
20.48, p <0.05), and of Dose (F(5,72) = 16.36, p <0.05), but no interaction 
between Pre-treatment and Dose (F(5,72) = 1.04, ns). 
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Figure 2.1.  Locomotor activating effects of SKF81297 in MDMA and 
vehicle pre-treated rats. Symbols represent the mean (+SEM) number of 
activity counts. Locomotor counts are summed into bins of 5 minute 
intervals with time ‘0’ being the time of drug injection. 
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Figure 2.2 below presents the above data as total locomotor counts 
following the injection of various doses of SKF81297. Analysis on total 
locomotor activity counts was conducted by using a 2-way ANOVA 
(Pre-treatment x Dose) with post hoc contrasts. Post hoc contrasts 
revealed an effect of pre-treatment for the 0.0 mg/kg groups (F(1,12)= 
14.64, p< 0.05), the 1.0 mg/kg groups (F(1,12)=14.0, p< 0.05), the 2.0 
mg/kg groups  (F(1,12)= 5.68, p< 0.05) and the 4.0 mg/kg groups 
(F(1,12)= 5.66, p< 0.05). 
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Figure 2.2.  Mean total locomotor counts (+SEM) on challenge day 
during the 60 minute post injection period with for vehicle and MDMA 
(10.0 mg/kg i.p.) pre-treated rats. Numbers above each column represent 
the sample size used. * difference from vehicle pre-treated group 
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Effects of SCH23390 in MDMA sensitised rats 
 
Following the sensitisation regimen of 5 daily injections of MDMA (0.0 or 
10.0mg/kg) and 2-day withdrawal effects of the D1–like antagonist, 
SCH23390, on the locomotor activating effect of 5.0 mg/kg MDMA was 
measured. Figure 2.3 shows locomotor activity as a function of time on test 
day (day 8). A three-way ANOVA [Pre-treatment (10.0 MDMA or vehicle) X 
Dose (0.0, 0.01, 0.02, and 0.04) X Time (12 five minute bins)] revealed a 
main effect of Pre-treatment (F(1,54) = 13.40, p <0.05), and Dose (F(3,54) = 
4.74, p <0.05), but no interaction between Pre-treatment and Dose (F(3,54) = 
1.29, ns). 
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Figure 2.3.  Locomotor activating effects of SCH23390 in MDMA and 
vehicle pre-treated rats. Symbols represent the mean (+SEM) number of 
activity counts. Locomotor counts are summed into bins of 5 minute intervals 
with time ‘0’ being the time of drug injection. 
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Figure 2.4 shows the above data presented as total locomotor counts 
following the injection of MDMA. A one-way ANOVA on data from vehicle 
pre-treated animals failed to reveal a main effect of Dose (F(3,27) = 1.79, ns). 
There was however a main effect of dose in the MDMA pre-treated rats 
(F(3,27) = 3.30, p<0.05).  In the MDMA pre-treated group, post hoc analysis 
showed the  0.04 SCH23390 dose significantly decreased MDMA produced 
hyperactivity (F(1,13) = 13.80, p<0.05). 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 2.4.  Effects of SCH 23390 on MDMA-(5.0 mg/kg) produced 
hyperactivity in vehicle and MDMA pre-treated rats. Symbols represent 
the mean number of activity counts (+SEM). Numbers in brackets above 
each column is the sample size. * difference from vehicle pre-treated 
group 
 
Because there was a sensitised response to MDMA, the data from vehicle and 
MDMA pre-treated rats were rescored as a  percentage change from 
‘baseline’ responding in Figure 2.5 below. A two-way ANOVA [Pre-
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treatment (10.0 MDMA or vehicle) X Dose (0.0, 0.01, 0.02, and 0.04)] failed 
to reveal a significant effect of Pre-treatment (F(1,54) = 0.24, ns) or a 
significant interaction between Pre-treatment and Dose (F(3,54) = 0.22, ns) 
but a significant main effect of Dose was obtained (F(3,54) = 4.88, p<0.05). 
Subsequent post hoc analysis with a one-way ANOVA on vehicle pre-treated 
rats revealed that the 0.04 dose significantly reduced MDMA-produced 
hyperactivity (F(1,14) 6.50, p <0.05). In the MDMA pre-treated group the 
0.04 dose of SCH 23390 also significantly decreased MDMA-produced 
hyperactivity (F(1,14) 13.80, p <0.05). 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 2.5.  Effect of SCH 23390 on MDMA (5.0 mg/kg) produced 
hyperactivity in vehicle and MDMA-pre-treated rats. Data are expressed 
as mean percent change from vehicle (+SEM). * difference from vehicle 
pre-treated group. 
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Experiment 2b Results. 
 
Effects of Apomorphine in MDMA sensitised rats 
 
Figure 2.6 shows the effect of apomorphine in vehicle and MDMA pre-
treated rats. A three-way ANOVA [Pre-treatment (10.0 MDMA or vehicle) X 
Dose (0.0, 0.5, 1.0, 2.0 and 4.0) X Time (12 five minute bins)] revealed a 
main effect of Pre-treatment (F(1,72) = 20.93, p <0.05), and of Dose (F(4,72) 
= 11.97, p <0.05). There was also a significant interaction between Pre-
treatment and Dose (F(4,72) = 3.76, p <0.05). 
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Figure 2.6.  Locomotor activating effects of apomorphine in MDMA and 
vehicle pre-treated rats. Symbols represent the mean (+SEM) number of 
activity counts. Locomotor counts are summed into bins of 5 minute 
intervals with time ‘0’ being the time of drug injection. 
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Figure 2.7 below presents the above data expressed as total post injection 
locomotor counts. Analysis on total locomotor activity counts was conducted 
by using a 2-way ANOVA (Pre-treatment x Dose) with post hoc contrasts. 
Post hoc results revealed that MDMA pre-treated rats were more responsive 
to the 2.0mg/kg (F(1,14)= 6.76, p< 0.05), and the 4.0 mg/kg (F(1,12)= 6.97, 
p< 0.05) doses. 
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Figure 2.7.  Mean total locomotor counts (+SEM) on challenge day 
during the 60 minute post injection period with for vehicle and MDMA 
(10.0 mg/kg i.p.) pre-treated rats. Numbers above each column represent 
the sample size used. * difference from vehicle pre-treated group 
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Effects of eticlopride in MDMA sensitised rats 
 
 
Figure 2.8 shows the effect of eticlopride on MDMA-produced locomotor 
activity in the vehicle and MDMA pre-treated rats. A three-way ANOVA 
[Pre-treatment (10.0 MDMA or vehicle) X Dose (0.0, 0.05, 0.1, and 0.2) X 
Time (12 five minute bins)] was conducted. There was no main effect of Pre-
treatment (F(1,50) = 2.29, ns), or interaction between Pre-treatment and Dose 
(F(3,50) = 1.21, ns) but a main effect of  Dose (F(3,50) = 11.58, p <0.05) was 
produced  
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Figure 2.8.  Effects of eticlopride on MDMA-(5.0 mg/kg) produced 
hyperactivity in vehicle and MDMA pre-treated rats. Symbols represent 
the mean number of activity counts (+SEM). Numbers in brackets above 
each column is the sample size. Locomotor counts are summed into bins 
of 5 minute intervals with time ‘0’ being the time of drug injection. 
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Figure 2.9 shows the data presented as total post injection locomotor counts.  
There was a main effect of Dose for both the vehicle (F(3,23) = 4.35, P<0.05) 
and MDMA (F(3,27) = 8.23, p<0.05) pre-treated rats. A one-way ANOVA 
on the data from the vehicle and MDMA-pre-treated rats revealed that all 
doses of eticlopride reduced MDMA-produced hyperactivity (p <0.05).  
 
 
 
 
 
 
 
 
 
 
 
 
Figure 2.9.  Effects of eticlopride on MDMA (5.0 mg/kg) produced 
hyperactivity in vehicle and MDMA pre-treated rats. Symbols represent 
the mean number of activity counts (+SEM). Numbers in brackets above 
each column is the sample size. * difference from vehicle pre-treated 
group. 
 
 
Figure 2.10 presents the above data as a percentage change from baseline. A 
two-way ANOVA [Pre-treatment (10.0 MDMA or vehicle) X Dose (0.0, 
0.01, 0.02, and 0.04)] was conducted. There was a significant effect of Dose 
(F(3,50) = 11.48, p<0.05) but the effect of  Pre-treatment (F(1,50) = 0.09, ns) 
or the interaction between  Pre-treatment and Dose (F(3,50) = 0.51, ns) were 
not significant.  
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Figure 2.10.  Effect of eticlopride on MDMA (5.0 mg/kg) produced 
hyperactivity in vehicle and MDMA-pre-treated rats. Data are expressed as 
mean percent change from vehicle (+SEM).  
 
Effects of Lower Doses of Eticlopride in MDMA sensitised rats 
 
In the previous groups, the lowest dose of eticlopride produced a large 
suppression of MDMA-produced activity in both groups. Therefore, several 
groups were subsequently tested with a lower dose range. Figure 2.11 shows 
the time course of MDMA (5.0 mg/kg) produced hyperactivity following this 
lower dose pre-treatment. A three-way ANOVA [Pre-treatment (10.0 MDMA 
or vehicle) X Dose (0.03, 0.01, 0.003 and 0.0) X Time (12 five minute bins)] 
was conducted. There was a significant main effect of Dose (F(3,41) = 3.15, 
p<0.05) but no significant main effect of Pre-treatment (F(1,41) = 1.49, ns) or 
a significant interaction between Pre-treatment and Dose (F(3,41) = 2.06, ns). 
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Figure 2.11.  Effects of low doses of eticlopride on MDMA (5.0 mg/kg) 
produced hyperactivity in vehicle and MDMA pre-treated rats. Symbols 
represent the mean number of activity counts (+SEM).Numbers in 
brackets above each column is the sample size. Locomotor counts are 
summed into bins of 5 minute intervals with time ‘0’ being the time of 
drug injection. 
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Figure 2.12 shows the data above presented as total locomotor counts 
following the injection of MDMA. A two way ANOVA revealed a 
significant main effect of Dose (F(3,41) = 3.15, p<0.05). A one-way 
ANOVA showed a significant main effect of Dose in the MDMA (F(3,22) = 
5.86, p<0.05) pre-treated groups but not in the vehicle pre-treated groups 
(F(3,22) = 1.78, ns). A one-way ANOVA on MDMA pre-treated rats showed 
all but the 0.003 dose to be significantly reduced compared to that of the 0.0 
dose (p <0.05).  
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Figure 2.12.  Effects of eticlopride on MDMA (5.0 mg/kg) produced 
hyperactivity in vehicle and MDMA pre-treated rats. Symbols 
represent the mean total number of activity counts (+SEM). Numbers 
in brackets above each column is the sample size. 
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Experiment 2c Results. 
 
Effects of RS102221 in MDMA sensitised rats 
 
Figure 2.13 shows the effect of RS102221 in vehicle and MDMA pre-treated 
rats. A three-way ANOVA [Pre-treatment (10.0 MDMA or vehicle) X Dose 
(0.0, 0.25, 0.5, and 1.0) X Time (12 five minute bins)] revealed a significant 
main effect of Pre-treatment (F(1,50) = 54.26, p<0.05) and a significant 
interaction between Pre-treatment and Dose (F(3,50) = 3.99, p<0.05) , but the 
effect of Dose was not significant (F(3,50) = 1.06 ns). 
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Figure 2.13.  Effects of RS102221 on MDMA (5.0 mg/kg) produced 
hyperactivity in vehicle and MDMA pre-treated rats. Symbols 
represent the mean number of activity counts (+SEM). Numbers in 
brackets above each column is the sample size. Locomotor counts 
are summed into bins of 5 minute intervals with time ‘0’ being the 
time of drug injection. 
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Figure 2.14 shows the data above presented as total number of locomotor 
counts following the injection of 5.0mg/kg MDMA. A one-way ANOVA on 
vehicle data showed no effect of Dose (F(3,27) = 1.11, ns) but a one-way 
ANOVA on the data from the MDMA pre-treated groups revealed  a main 
effect (F(3,23) = 3.10, p<0.05).  Post hoc analysis revealed that the doses of 
0.5 and 1.0 mg/kg RS102220 increased activity relative to the 0.25 mg/kg 
dose (p<0.05).   
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 2.14.  Effects of RS102221 on MDMA (5.0 mg/kg) produced 
hyperactivity in vehicle and MDMA pre-treated rats. Symbols represent 
the mean total number of activity counts (+SEM). Numbers in brackets 
above each column is the sample size. * difference from vehicle pre-
treated group 
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Figure 2.15 presents the above data as a percentage change from 
‘baseline’ (0.0 RS102221 dose) responding. A two-way ANOVA Pre-
treatment (10.0 MDMA or vehicle) X Dose (0.0, 0.25, 0.5 and 1.0mg/kg)] 
showed no significant effect of Pre-treatment (F(1,51) = 0.87, ns), no 
main effect of Dose (F(3,51) = 0.31, ns) but an interaction between Pre-
treatment and Dose (F(3,51) = 2.99, p<0.05). A one-way ANOVA 
showed a difference in MDMA pre-treated data (F(3,26) = 3.10, p<0.05) 
with the difference between the 0.25  and 1.0 dose F(1,14) = 7.39, 
p<0.05). 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 2.15.  Effect of RS102221 on MDMA (5.0 mg/kg) produced 
hyperactivity in vehicle and MDMA pre-treated rats. Data are expressed 
as mean percent change from vehicle (+SEM).  
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Experiment 2 Discussion 
 
In accordance with experiment 1, and previous literature, the present study 
demonstrated that pre-exposure to MDMA produces sensitisation to its 
locomotor producing effects. The locomotor activating effects of 
amphetamine are widely agreed to be mediated by DA (Kalivas & Stewart, 
1991; Nestler, 1992; Robinson & Berridge, 1993: Segal, 1989) and the 
present investigation demonstrated hyperlocomotor producing effects of 
repeated MDMA might also reflect sensitisation in underlying dopaminergic 
substrates.  
 
Following repeated exposure to MDMA the D1 agonist, SKF81297, produced 
a greater locomotor response when compared to vehicle pre-treated animals. 
The leftward shift in the dose response curve suggests a sensitisation of the 
D1 receptor. Repeated exposure to amphetamine also produced D1 receptor 
sensitivity in sub-cortical structures such as the NAc (Henry & White, 1991) 
and VTA (Vezina, 1996). Further, pre-treatment with the D1–like receptor 
antagonist, SCH 23390, blocked both the development and expression of 
amphetamine produced behavioural sensitisation (Vezina, 1996; Vezina and 
Stewart 1989). In contrast, the development of MDMA-produced 
sensitisation was unaffected by pre-treatment with SCH23390 while but 
SCH23390 dose dependently blocked the expression of sensitisation (Ramos 
et al., 2004).   
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In the current investigation, the administration of the D1–like receptor 
antagonist, SCH23390, decreased MDMA produced locomotor activity to a 
comparable degree in both MDMA and vehicle pre-treated animals. This 
reduction in the response to MDMA supports the idea that the D1 receptor 
plays a role in the expression of MDMA-produced hyperactivity, as has been 
previously suggested (Daniela et al., Ball et al., Ramos et al.,). The failure to 
observe an increased potency of SCH 23390 in the MDMA pre-treated rats is 
not consistent with the idea that the D1 receptor became supersensitive as a 
result of pre-exposure.  
 
One possibility is that the effects of SCH 23390 are due to activity at 
alternate receptor sites. Thus, although SCH23390 has been extensively used 
as a dopamine D1 receptor antagonist (Bourne, 2001) it also binds with high 
affinity to 5-HT2C receptors functioning as an antagonist (Millan, Newman-
Tancredi, Quentric, & Cussac, 2001). Administration of 5-HT2C receptor 
antagonists increased DA firing rates and 5-HT2C receptor agonists decreased 
firing rates (Di Matteo et al. 2000; Gobert et al. 2000). Therefore, it is 
possible that these two effects of SCH 23390 counteracted each other. That 
is, the DA blocking effects would be expected to result in an antagonism of 
MDMA-produced hyperactivity whereas the effects on the 5HT2c receptor 
would be expected to enhance MDMA-produced hyperactivity.  Indeed, the 
current results support this hypothesis as the selective 5-HT2C antagonist, 
RS102221, potentiated MDMA-produced hyperactivity in the MDMA pre-
treated rats.   
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The locomotor activating effects of the mixed D1/D2 agonist, apomorphine, 
were increased across a range of doses in MDMA sensitised animals. 
Apomorphine is non-selective but it has greater affinity for the D2 receptor 
(Li, et al., 2006). The Ki for the D2 receptor was 5 nanomolars (nM) and for 
the D1 receptor it was 500 nM (Missale, Nash, Robinson, Jaber, & Caron, 
1998). Apomorphine therefore is a preferential DA D2 agonist.  
 
Following amphetamine pre-treatment, there have been reports of either no 
change or down regulation of D2 receptors (Muller and Seeman, 1979; 
Robinson & Becker, 1986) although DA D2 receptor agonists have been 
shown to induce augmented behavioural responses in sensitised rats (Levy et 
al., 1988; Ujike et al., 1990). It has been suggested, however, that 
sensitisation is accompanied by an increased sensitivity of the high-affinity 
D2 post synaptic receptors (Seeman, Tallerico, Ko, Tenn, & Kapur, 2002; 
Seeman, McCormick & Kapur, 2007). This might explain the increased 
apomorphine-produced hyperactivity observed in the present study.  
 
A transient decrease in the sensitivity of D2 auto receptors has also been 
reported following repeated amphetamine administration (Wolf et al., 1993). 
To ascertain whether this could explain the supersensitive response to 
apomorphine, effects of a low dose of the D2 antagonist, eticlopride, which 
would have preferentially blocked D2 autoreceptors (Salmi, Malmgren, 
Svensson, Ahlenius, 1998), were determined. Under these circumstances, an 
increase in MDMA -produced hyperactivity might have been expected. This 
was not observed, however, even when extremely low doses of eticlopride 
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were administered. These data are, therefore, not consistent with the idea that 
the autoreceptor became desensitised. Rather, the data suggest that MDMA 
pre-treatment resulted in an up-regulation of the postsynaptic D2 
mechanisms.  
 
Sustained receptor activation by DA agonists may alter the D2 coupling of the 
G-protein without alteration of receptor densities (Rudissaar, Harro, Pruus, 
Rinken, & Allikmets, 2008). Extracellular signals produce increases or 
decreases of second messengers such as cyclic adenosine monophosphate 
(cAMP) resulting in a number of biological responses (Gelowitz & Berger, 
2001). For example, when cocaine is chronically administered there is 
increased adenylyl cyclase and cAMP dependent protein kinase in neurons in 
the NAc (Miserendino, & Nestler, 1995). Further, administration of cholera 
toxin in the NAc, activating adenylyl cyclase, enhances the acute locomotor 
activating effects of amphetamine (Cunningham & Kelley, 1993). The 
uncoupling of the G-protein had been reported following chronic 
administration of the D2 agonist, apomorphine, without altering locomotor 
activity (Rudissaar, et al., 2008). However, supersensitivity of the D2 
receptors following unilateral lesions of the striatal system, enhanced Gi 
coupling and subsequent locomotor responses (Cai, Wang, & Friedman, 
2002; Cai, Zhen, Uryu, & Friedman, 2000). These data suggest that in 
neurons expressing D2 receptors an enhanced Gi coupling  may be produced 
following amphetamine sensitisation however, the exact mechanisms of 
action are, as yet, still unclear (Rudissaar et al., 2008; Schwendt, &  
McGinty, 2007; Traynor & Neubig, 2005). It is seemingly likely however, 
 94 
that during the MDMA sensitising regimen changes in coupling to the 
adenylyl cyclase inhibiting D2 G-protein occurred. This may explain the 
differential locomotor producing effects of the D2 agonist and antagonist. 
 
Experiment 2 summary 
 
The current results are consistent with the hypothesis that locomotor 
sensitisation to MDMA is mediated by DA receptor mechanisms. There was 
cross-sensitisation between the effects of MDMA and both the D1-like 
agonist, SKF81297, and the preferential DA D2-like agonist, apomorphine. 
These effects were not, however, reflected in sensitised responses to the 
antagonists. Whereas the failure for the response to SCH 23390 to be 
increased in MDMA sensitised rats might be due to non selective effects, the 
failure to observe differential effects of the D2-like antagonist, eticlopride, 
suggests that there is an alteration in coupling of the D2 receptor mechanisms 
under conditions of D2 blockade.   
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Experiment 3: Changes in potency of reinforcement of MDMA as 
measured in the self-administration paradigm following repeated 
intermittent exposure to MDMA 
Background 
 
There is now strong evidence supporting the relationship between drug 
induced changes in mesolimbic dopamine and the rewarding effects and 
abuse liability of drugs as modelled by self administration. For example, 
neurotoxic lesions (Roberts, Koob, Klonoff, & Fibiger, 1980) or 
administration of D1-like and D2-like receptors antagonists (Caine & Koob 
1994; Pierre & Vezina, 1998; Woolverton & Virus, 1989) produced a 
rightward shift in the dose effect curve. Conversely, administration of direct 
or indirect (Schenk et al, 2003; Spealman, Barrett-Larimore, Rowlett, Platt, 
& Khroyan, 1999) dopamine agonists produced a leftward shift (Caine & 
Koob, 1994) supporting the idea that dopaminergic mechanisms underlie the 
reinforcing effects of drugs of abuse. 
 
The magnitude of the initial reinforcing effects of drugs was inversely related 
to drug dose. Thus, self-administration was acquired more rapidly when 
higher doses were available (Schenk et al, 1993; Carroll & Lac, 1997). 
Following systemic pre-treatment with amphetamine or cocaine, latency to 
acquisition of self-administration was reduced, suggesting an enhancement of 
the initial reinforcing effects (Horger et al., 1990; 1992; Schenk & Partridge, 
2000; Vezina et al., 1999). Pre-treatment with drugs other than the self-
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administered drug has also been shown to decrease the latency to acquisition 
of self-administration (Schenk et al, 1993; Schenk & Izenwasser, 2002). 
These findings suggest that pre-exposure to psychostimulants may increase 
their reinforcing effects and may produce neuroadaptations that are common 
and might underlie the abuse liability of some drugs. Given the role of 
dopamine in self administration it further suggests that these 
neuroadaptations are within the dopamine system.  
 
Latency to acquisition of self-administration of other drugs of abuse was 
inversely related to drug dose; higher doses led to more rapid acquisition 
(Schenk et al., 1991, 1993; Schenk & Partridge, 2000). In the case of 
MDMA, only one report has provided data on the relationship between 
acquisition rate and available dose for self-administration. In that study 
(Schenk et al., 2007), two doses of MDMA (0.25 and 1.0 mg/kg/infusion) 
were available. Latency to acquisition did not differ as a function of dose 
and, in both cases, latency to acquire self-administration was more variable 
and longer than the latency to acquire cocaine (0.5 mg/kg/infusion) self-
administration.  
 
Pre-exposure to MDMA facilitated cocaine self-administration (Fletcher, 
Robinson, & Slippoy, 2001), suggesting a sensitised response but, to my 
knowledge, there have not been studies that have examined the effects of 
prior exposure to MDMA on latency to acquisition of MDMA self-
administration.  
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Experiment two demonstrated an augmented locomotor response to both D1 
and D2 agonists following repeated MDMA administration. It is therefore 
hypothesised that a sensitised dopamine response would facilitate the 
acquisition of self-administration. In the current experiment two doses of 
MDMA were chosen for this acquisition study (0.5 and 1.0 mg/kg/infusion). 
Both doses were based on previous research showing acquisition of MDMA 
within approximately 12 days (Schenk, et al., 2003; 2007).  
 
Materials and methods 
 
1Subjects 
Subjects were male Sprague-Dawley rats bred in the vivarium at Victoria 
University of Wellington. They were initially housed in hanging 
polycarbonate cages in groups of four to six per cage, but once they reached 
weights of 250–275 g, they were individually housed. The humidity (74%) 
and temperature (21C) controlled animal colony was maintained on a 12:12-h 
light/dark cycle with lights on at 0700 hours. Food and water were freely 
available except during the short duration (2 hour) self-administration tests 
described below. 
 
Surgery 
Rats were implanted with a silastic catheter in the right jugular vein. The rats 
were deeply anesthetized with ketamine (60.0 mg/kg, IP) and pentobarbital 
                                                 
1
 The Materials and methods sub-sections named ‘subjects’, ‘surgery’ and ‘apparatus’ have 
previously been described in Schenk S, Gittings D, Johnstone M, Daniela, E. (2003). 
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(20.0 mg/kg, IP), the external jugular vein was isolated, a catheter inserted 
and the distal end (22 ga stainless steel tubing) was passed subcutaneously to 
an exposed portion of the skull, where it was fixed to embedded jeweller’s 
screws with dental acrylic. Each day, the catheters were infused with 0.1 ml 
of a sterile saline solution containing heparin (30.0 IU/ ml) and ampicillin 
(250,000 IU/ml) to prevent infection and the formation of clots. The rats were 
allowed 5 days post-surgery for recovery prior to behavioural testing.  
 
Apparatus 
 
Self-administration training and testing were conducted in test chambers 
(Med Associates, ENV 001) enclosed in sound attenuating closets. The 
testing room containing the 31 test chambers was humidity (55%) and 
temperature (21ºC) controlled. Each chamber was equipped with two levers 
and a stimulus light. Depression of one lever (the active lever) resulted in an 
infusion of drug. Depression of the other lever (the inactive lever) was 
without programmed consequence. Infusions were in a volume of 0.1 ml 
delivered over 12.0 sec via Razel pumps equipped with 1.0 rpm motors and 
20.0 ml syringes.  
 
Procedure 
 
Rats received a pre-treatment consisting of MDMA (0.0 (n = 17) or 
10.0mg/kg (n = 18)), i.p) as per the 5 day sensitising regimen described in 
the general procedure section of Experiment 1. This was followed by a two 
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day withdrawal period. Catheters were implanted the following day and 
animals were allowed to recover for a further 5 days. Therefore, self 
administration testing began 9 days following the pre-treatment phase. This 
withdrawal period was chosen because a sensitised response to MDMA was 
produced 9 days following repeated MDMA administration in Experiment 
1b. 
 
Self-administration tests were conducted during daily 2 hour sessions. Every 
session began with an experimenter delivered infusion of MDMA. 
Thereafter, each depression of the active lever (FR1 reinforcement schedule) 
resulted in an automatic infusion of MDMA [0.5 or 1.0 mg/kg/infusion] 
paired with the illumination of a stimulus light located directly above the 
active lever. 
Testing continued for 14 days or until the number of active lever responses 
was greater than 10, and a preference for the active lever was demonstrated, 
as per Daniela et al., (2006) and Schenk et al., (2007).  The number of days 
required to meet this criterion was determined for each rat.  
Results 
 
Figure 3.1 shows the cumulative percentage of rats in each pre-treatment 
group that acquired MDMA self-administration as a function of days and 
MDMA dose. For all rats, regardless of pre-treatment and subsequent self-
administration dose, a total of 46% reached the self-administration criterion. 
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Figure 3.1. Cumulative percentage of rats that acquired MDMA self-
administration as a function of days of testing, pre-treatment condition and 
MDMA dose. 
 
 
Of the vehicle pre-treated group that self-administered 1.0mg/kg/infusion 
nearly 40% met the criteria for acquisition by day 5 and in this group the 
highest percentage of rats that acquired self-administration during the 14 day 
test period. There was an increase in the latency to acquisition for the vehicle 
pre-treated group that self-administered the lower dose of 0.5 mg/kg/infusion 
MDMA. The MDMA pre-treated rats were slower to acquire self-
administration and a lower percentage met the criteria within the test period 
when compared to their vehicle pre-treated counterparts. 
 
Rats pre-exposed to 10.0mg/kg MDMA for five days and tested with 1.0 
mg/kg/infusion MDMA had an average daily intake of 9.80mg/kg. Rats pre-
exposed to vehicle for five days and tested 1.0 mg/kg/infusion MDMA had 
an average daily intake of 8.51mg/kg. There was no difference in average 
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daily intake between MDMA and vehicle pre-exposed groups in the 
1.0mg/kg/inf condition [t(6) =1.45, p= 0.196]. 
 
Rats pre-exposed to 10.0 MDMA for five days and tested with 0.5 
mg/kg/infusion MDMA had an average daily intake of 3.59mg/kg. Rats pre-
exposed to vehicle for five days and tested 0.5 mg/kg/infusion MDMA had 
an average daily intake of 6.90mg/kg. There was a significant difference in 
average daily intake between MDMA and vehicle pre-exposed groups in the 
0.5mg/kg/infusion condition [t(4) =-3.396, p= 0.027] with vehicle animals 
having a higher daily average intake. 
 
Figure two shows the range of responses on the active and inactive lever for 
all rats that failed to reach criterion. The failure for these rats to acquire was 
related to the criterion of 10 responses rather than lack of active lever 
preference. 
Table 2. 
 
 
 
 
 
 
 
 
Table 2. Range of responses on the active and inactive lever for rats that 
failed to reach criterion.  
  Range of responses 
Pre-treatment MDMA 
(mg/kg/infusion) 
 
Inactive lever Active lever 
 
Vehicle (n=6) 
 
0.5 0.3 – 3.1 1.6- 3.6  
Vehicle (n=3) 1.0 0.0 - 5.0 0.6 - 5.3 
MDMA (n=5) 0.5 0.2 - 3.6 1.4 – 4.6 
MDMA (n=5) 1.0 0 - 3.2 0.8 – 4.6 
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Discussion 
 
The present study was designed to determine whether pre-exposure to 
MDMA, under conditions that produced sensitisation to the locomotor 
activating effects of MDMA, decreased the latency to acquisition of MDMA 
self-administration.  Somewhat surprisingly, pre-treatment with MDMA did 
not decrease latency to acquisition. Indeed, in comparison to vehicle pre-
treated animals there was an increased latency to acquisition for the MDMA 
pre-treated rats.  
 
An inverse relationship between drug dose and latency to acquisition of self-
administration of other drugs of abuse has been demonstrated (Schenk et al., 
1991, 1993; Schenk & Partridge, 2000). Consistent with these findings 
latency to acquisition of MDMA self-administration was shorter for the 
group that self-administered the higher dose and a higher percentage of these 
rats met the criterion for acquisition within the temporal parameters of this 
experiment.  
 
In contrast to results of other studies, however, MDMA pre-treatment failed 
to decrease the latency to acquisition of self-administration. One possibility is 
that the doses of MDMA tested were too high to allow reliable decreases to 
be observed. Indeed, pre-exposure to amphetamine decreased the latency to 
acquisition of  self-administration of low doses (Piazza, et al., 1989; Pierre & 
Vezina, 1997) but failed to alter acquisition of self-administration when 
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higher doses were available (Lorrain, Arnold, & Vezina, 2000; Mendrek, 
Blaha, & Phillips, 1998).  
 
Another possibility is that pre-treatment with MDMA as in the present study 
sensitised the rats to the aversive effects of MDMA and hence delayed the 
acquisition of self administration. Indeed, there have been several reports of 
MDMA-produced aversion. A conditioned taste aversion was produced by 
MDMA (Lin, Atrens, Christie, Jackson, & McGregor, 1993).   MDMA also 
increased the latency to emerge from a darkened hide box (McGregor, et al., 
2003) and reduced activity on the elevated plus maze (Bull, Hutson, & Fone, 
2004), suggesting an anxiogenic effect (Navarro & Maldonado 2002). These 
initial aversive properties of MDMA might explain the gradual acquisition of 
self-administration in vehicle and also in MDMA-pre-treated rats.  
 
A final possibility for the failure of MDMA pre-treatment to enhance the 
reinforcing effects of MDMA relates to pharmacological effects of repeated 
exposure. It has been suggested that reinforcing efficacy of drugs is related to 
the relative effects on DA and 5HT neurotransmission. More specifically, it 
has been suggested that increased serotonergic effects are associated with 
decreased potency as a reinforcer. This idea is based on a number of 
empirical findings.  Firstly, administration of the 5-HT precursor tryptophan, 
which increases brain 5-HT synthesis, decreased self-administration of 
cocaine (McGregor, Lacosta, & Roberts, 1993) and amphetamine (Smith, Yu, 
Smith, Leccese, & Lyness, 1986). Secondly, pre-treatment with 5-HT 
reuptake inhibitors reduced cocaine self-administration (Carroll, Lac, 
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Asencio, & Kragh, 1990). Thirdly, the motivation to self-administer 
amphetamine analogues with greater 5-HT potency, but equipotent DA 
potency, was reduced as measured by progressive ratio responding (Wee, et 
al., 2005).  
 
A number of studies have shown that  MDMA increased 5-HT levels 
(Kalivas et al., 1998) and that chronic or long term exposure compromised 5-
HT neurotransmission (Battaglia, Yeh, & De Souza, 1988). These 
pretreatment regimens, however, were more stringent than those used in this 
study. Therefore the effects of the current regimen of MDMA on tissue levels 
of DA, 5-HT and their major metabolites were measured in Experiment 4. 
 
Experiment 4: Alterations of brain amine levels following repeated 
intermittent administration of MDMA 
Background 
 
Amphetamine administration increased DA levels and synaptic dopamine 
overflow throughout various neural substrates such as the striatum (Kolta, et 
al., 1985), prefrontal cortex (Ichikawa, Chung, Li, Dai, & Meltzer, 
2002),VTA (Wolf, et al., 1993), NAc (Kalivas & Stewart, 1991; Robinson & 
Berridge, 1993) and all DA terminal fields (Vezina, 2004). Because local 
application of amphetamine into the VTA, but not into the NAc, produced a 
sensitised locomotor response (Cador, et al., 1995; Kalivas & Weber, 1988), 
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it has been suggested that neuroadaptations initiated by the acute increase in 
synaptic DA in the VTA mediate sensitised hyperactivity (Vezina, 2004).  
 
The relationship between augmented DA release and the observation of 
locomotor sensitisation has been equivocal. In some studies, concordance 
between sensitised behavioural and neurochemical responses has been 
reported. For example, 7 days after repeated amphetamine administration 
there were increases in amphetamine-produced DA in the NAc of rats which 
coincided with sensitised hyperlocomotion (Scholl, Feng, Watt, Renner, & 
Forster, 2009). Other studies, however, have failed to replicate these effects. 
In one, sensitised hyperlocomotion was observed 7 days after withdrawal but 
there were no differences in amphetamine induced dopamine overflow in 
nucleus accumbens or striatal tissue (Weinstein, Narayanan, Byrnes, Uretsky, 
& Wallace, 1997). In another, sensitised locomotor activity observed 2 days 
following withdrawal that was not associated with an augmented DA 
response; a sensitised DA response was not observed until 10 days later 
(Kuczenski, Segal, & Todd, 1997; Wolf, et al., 1993). Finally, after repeated 
high doses of amphetamine, amphetamine-produced stereotypical behaviour 
was observed but there were no changes in amphetamine-produced increases 
in NAc DA levels (Segal, & Kuczenski 1999). These data suggest that, under 
certain regimens of administration, the behavioural and neurochemical 
indices of sensitisation to amphetamine may be dissociated. 
 
Following acute administration, MDMA increased extracellular synaptic 5-
HT and produced a moderate increase in dopamine levels (Schmidt, 1987). 
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Following chronic or high dose administration, however, MDMA reduced 
brain levels of 5-HT, tryptophan hydroxylase and the 5-HT metabolite, 5-
HIAA, (see Capela et al., 2009 for a review). Under some conditions, 
repeated administration of MDMA also produced behavioural and 
neurochemical sensitisation (Bubar, et al. 2004; Kalivas, et al, 1998; 
Yamamoto & Spanos, 1988). Behavioural sensitisation was accompanied by 
a moderate decrease in ventral striatal 5-HT (Ludwig, Mihov, & Schwarting, 
2007).   
 
In order to determine whether sensitisation produced in the present 
investigations was accompanied by changes in overall levels of 5-HT or DA, 
rats were pre-treated with 10.0 mg/kg MDMA in a manner that induced 
sensitisation and sacrificed two days after their final drug administration. 
Using HPLC tissue levels of DA, its metabolite HVA, 5-HT and its 
metabolite 5-HIAA were measured. It is hypothesised that, in accordance 
with previous literature, there will be a reduction in 5-HT levels of brain 
neurotransmitter along with its metabolite 5-HIAA. It is not predicted that 
there will be any change in DA or HVA. 
 
General Procedure 
 
Rats were pre-treated once daily with MDMA (0.0, 10.0 mg/kg) or, as a 
comparison, amphetamine (2.0 mg/kg I.P) for five days in as described in the 
general sensitisation protocols, experiment 1. Following two days withdrawal 
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rats were rendered unconscious with CO2 in an air tight chamber, decapitated 
and the brains rapidly removed.  
 
Brain Dissection 
 
Whole brains were placed in a stainless steel block for dissection into 1.0 mm 
coronal slices ( Heffner, Hartman, & Seiden, 1980). Slices were placed onto 
an inverted petri dish chilled by ice. The dorsal striatum, NAc, frontal cortex 
and amygdala and were dissected, placed in vials, weighed and stored at -80º 
C until analysed.  
 
HPLC analysis 
 
Tissue samples were homogenised in 0.1 N perchloric acid and centrifuged at 
10 000g for 30 min at 4º C. The supernatant was filtered and injected onto a 
high-performance liquid chromatography system (Agilent 1100 series) with 
electrochemical detection. The injection volume was 10 µL for the striatum 
and 20 µl for the other regions. 5-HT, 5-HIAA, DA and HVA were separated 
using a C18 reversed phase column (150 × 4.6 mm, 5 µm particle size; 
Eclipse XDB-C18, Agilent, USA). The mobile phase consisted of NaH2PO4 
(75 mM), octane-1-sulphonic acid (1.7 mM), EDTA (0.25 mM), 
triethylamine (100 µL/L) and methanol (10%), and was adjusted to pH 3 with 
phosphoric acid. The flow rate was 1 ml/min. Detection was performed using 
a coulometric detector (Coulochem III, ESA, USA). The guard cell potential 
was set at 450 mV and the analytical cell potential at 400 mV. 
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Chromatograms were acquired with ChemStation software. Concentrations 
are expressed as ng per mg of tissue. 
 
Peak areas corresponding to the DA, 5-HT, HVA and 5-HIAA were 
measured and concentrations were determined from the regression curve 
obtained with external standards. Working external standards (500 – 15.125 
ng/ml in 0.1N perchloric acid) were prepared daily from 1 mg/ml stock 
solutions and kept at -80°C.  
 
Results 
 
Figure 4.1 below shows a chromatogram of 5-HT, 5-HIAA, DA and HVA 
standards separated using a C18 reversed phase column.  
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Figure 4.1.  Chromatogram of amine standards injected onto a C18 
reversed phase column 
 
Table 4.1 presents results of the analyses of each of five brain regions from 
control rats and those that had undergone a sensitising regimen of MDMA 
(10.0 mg/kg I.P) or amphetamine (2.0mg/kg. I.P). Amphetamine and MDMA 
were compared to vehicle groups with a Bonferonni correction applied. 
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Table 4.1.  Neurochemical concentrations in tissue of rats that received either vehicle, 
MDMA (10.0 mg/kg I.P) or amphetamine (2.0mg/kg. I.P) during a 5-day pre-
treatment regimen. ** = difference from vehicle pre-treated group (p< 0.01), n=6 
except for the ‘Amygdala MDMA’ group where n= 5. 
 
Structure  Concentration ng/mg tissue 
  DA 5-HIAA HVA 5-HT 
Striatum      
 Vehicle 31.14 + 3.69 0.55 + 0.03 1.65 + 0.14 0.79 + 0.11 
 Amph 30.26 + 2.93 0.52 + 0.04 1.44 + 0.08 0.79 + 0.11 
 MDMA 30.76 + 3.05 0.46 + 0.03 1.48 + 0.13 0.74 + 0.08 
      
Nucleus Acc      
 Vehicle 12.08 + 2.68 0.79 + 0.04 1.37 + 0.11 0.87 + 0.13 
 Amph 13.07 + 2.53 0.68 + 0.06 1.10 + 0.10 0.83 + 0.06 
 MDMA 13.91 + 3.49 0.63 + 0.04 1.09 + 0.11 0.86 + 0.14 
      
Frontal Cortex      
 Vehicle 0.20 + 0.04    0.54 + 0.03 0.08 + 0.01 0.98 + 0.14 
 Amph 0.20 + 0.01 0.43 + 0.03** 0.08 + 0.01 0.94 + 0.08 
 MDMA 0.22 + 0.03 0.38 + 0.02** 0.07 + 0.01 0.92 + 0.16 
      
Amygdala      
 Vehicle 0.88 + 0.16 0.62 + 0.06 0.11 + 0.01 1.12 + 0.14 
 Amph 0.88 + 0.16 0.52 + 0.07 0.07 + 0.01 1.18 + 0.18 
 MDMA 0.86 + 0.09 0.42 + 0.05 0.07 + 0.01 0.94 + 0.17 
      
Hippocampus      
 Vehicle 0.07 + 0.01    0.54 + 0.02 0.005 + 0.003 0.68 + 0.09 
 Amph 0.06 + 0.00 0.44 + 0.02** 0.000 + 0.000 0.75 + 0.07 
 MDMA 0.07 + 0.01 0.35 + 0.02** 0.003 + 0.002 0.75 + 0.07 
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Discussion 
 
A large number of studies have reported neurochemical effects of MDMA 
pre-treatment. In most studies, the MDMA pre-treatment regimen was 
substantive with animals exposed to doses of 20-40 mg/kg/day. These 
exposures typically resulted in behavioural tolerance rather than sensitisation 
to the behavioural effects of MDMA. Tolerance was accompanied by 
substantial decreases in both 5-HT and 5-HIAA (Marston et al., 1999; 
McNamara et al. 1995). The regimen in the current study was less extreme 
and produced a different profile of behaviour; i.e. sensitisation rather than 
tolerance. Differences in the neurochemical consequences were also observed 
in the present study.  
 
There were no significant effects of the daily exposures on 5-HT although 
there was a significant decrease in the primary metabolite, 5-HIAA, in two of 
the 5 sites measured. This finding is consistent with the decrease in 5-HIAA 
in the frontal cortex  previously reported (Ludwig, Mihov, & Schwarting, 
2008). Comparable effects were produced by repeated exposure to a 
sensitising regimen of amphetamine. 
 
A number of studies have also failed to observe changes in basal DA and 5-
HT levels, synthesis or metabolism following repeated exposure to 
amphetamine that resulted in sensitisation (Bonhomme, Cador, Stinus, Le 
Moal, & Spampinato, 1995; Paulson, et al., 1991). Other studies, however, 
have suggested that following more stringent exposure regimens alterations 
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in tissue levels were produced. For example, a reduction in levels of  5-HT 
and 5-HIAA in the striatum was observed 24 hrs after the last dose of a daily 
administration regimen of 5.0 mg/kg amphetamine (McMillen, Scott, & 
Williams, 1991). Additionally, chronic amphetamine administration in cats 
(twice daily increasing doses of 5-15mg/kg amphetamine for ten days) 
reduced levels of 5-HT and 5-HIAA up to50% in the cortex, hippocampus, 
striatum, brain stem and spinal chord when measured 9 days but not 14 days 
post withdrawal (Trulson & Jacobs, 1979).  
 
In the current results it is noticeable that the 5-HT metabolite 5-HIAA was 
reduced while levels of the parent molecule remained unchanged. Release 
and reuptake of 5-HT is the main source of extracellular 5-HIAA. Once 
released, the SERT moves the 5-HT molecules back into the presynaptic cell 
where it is bound into storage vesicles or deaminated to 5-HIAA. This 
metabolite is not stored but is passed back through to the extracellular area 
(Stenfors & Ross, 2004). Without 5-HT release there is a reduction in 5-
HIAA levels. A reduction in release could explain why there is no difference 
in absolute tissue levels of 5-HT but, at the same time, there is a reduction in 
5-HIAA levels. If there was a reduction in firing rates of serotonin neurons, 
differences in levels of 5-HIAA would be seen in all 5-HT terminal regions. 
Although only effects of MDMA or amphetamine were significant in two 
regions, for all regions there was a trend for reduced 5-HIAA.  
 
5-HT release is regulated by the 5-HT1A and 5-HT1B receptors with selective 
antagonists blocking both the feedback mechanism and increasing 
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extracellular 5-HT while reducing absolute 5-HIAA levels (Hjorth, et al., 
2000). (Note that this is an absolute decrease in 5-HIAA and as there is 1000 
times more extracellular 5-HIAA than 5-HT there remains a larger 
proportional amount of 5-HIAA). However, there is a differential role of the 
5-HT1A and the 5-HT1B receptor in mediating changes in 5-HIAA levels as a 
function of 5-HT. Administration of the 5-HT1A receptor antagonist, 
robalzotan, directly into the frontal cortex, increased citalopram-produced 
extracellular 5-HT and decreased 5-HIAA levels (Hjorth, 1998). 
Administration of the 5-HT1B receptor antagonist, GR127935, also increased 
citalopram induced increases in extracellular 5-HT levels, but no change in 5-
HIAA levels was produced. Although antagonism of both the 5-HT1A and the 
5-HT1B autoreceptors increased 5-HT levels, only antagonism of the 5-HT1B 
disrupted the normal inverse relationship between 5-HT and5-HIAA. 
Stenfors and Ross (2004) interpreted this as due to stimulation of 5-HT1B 
autoreceptors by the elevated synaptic 5-HT concentration resulting in 
decreased 5-HT release. Applied to the current results it may suggest that 
intermittent MDMA administration produces an altered 5-HT1B auto receptor 
state, reducing 5-HT release (but not overall storage levels) and subsequent 
decrease of 5-HIAA levels. 
 
Experiment 4 Summary 
 
In previous studies, pre-exposure to amphetamine or MDMA under 
conditions that produced sensitised behavioural responses did not alter tissue 
levels of either DA or 5-HT (Bonhomme, et al. 1995; Paulson, et al., 1991).  
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The current results are consistent with this except that decreased levels of the 
serotonin metabolite 5-HIAA was produced in the frontal cortex and 
hippocampus.  The reduction in 5-HIAA levels may be due to a disruption to 
the 5-HT1B autoreceptor. Further evidence for this could be obtained through 
a microdialysis assay of terminal regions of serotonin cells which would be 
hypothesised to show a reduction in extracellular levels of 5-HT. 
Electrophysiology studies would be required to confirm a reduction in tonic 
firing of 5-HT cells. 
 
General Discussion 
 
The aim of the current thesis was to determine (1) some of the parameters for 
induction and expression of locomotor sensitisation following repeated 
MDMA exposure (2) Changes in sensitivity of the dopamine receptor 
mechanisms in sensitisation, and (3) if sensitisation was linked to reductions 
in the potency of the reinforcing effects of MDMA as measured by self 
administration and (4) what, if any, long term alterations in brain tissue levels 
of amines resulted from repeated exposure to MDMA. A group of four 
experiments were used to evaluate the above questions and results can be 
briefly summarised in the following manner. 
 
1) A single dose of 10.0mg/kg MDMA administered daily for five 
days produces reliable behavioural sensitisation. 
2) Following the sensitisation regimen, there is cross sensitisation to 
D1 and D2 agonists. However, even though a dose dependent 
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reduction in MDMA produced responding is attenuated by D1 and 
D2 antagonists, the potency of these antagonists is not altered by 
MDMA pre-treatment. This suggests that there are underlying 
mechanisms other than just receptor hypersensitivity responsible for 
the augmented locomotor activating effect of MDMA following a 
sensitisation dosing regimen. 
3) The protocol that induces locomotor sensitisation does not decrease 
latency to acquisition of MDMA in the self- administration 
paradigm suggesting there are no changes in the potency of MDMA 
as a reinforcer after the current pre-treatment regimen 
4) Following five single daily injections of 10.0mg/kg MDMA there 
are only minor reductions in the 5-HT metabolite 5-HIAA and no 
change in other brain amines tested.  
 
Experiment one demonstrated that of the two pre-exposure regimens, pre-
treatment with 10.0 mg/kg/day MDMA was the more effective and that 
behavioural sensitisation, unlike amphetamine sensitisation, was relatively 
short-lived. A sensitising regimen of amphetamine has shown increases in 
DA overflow up to three months following drug exposure (Hamamura, et al., 
1991).  Further, sensitised locomotor activity was apparent one year 
following amphetamine exposure (Paulson, et al., 1991). This may suggest 
that persistent sensitisation does not occur under the current pre-treatment 
regimen of MDMA however, a clear sensitised locomotor response was 
evident in all of the behavioural assays. These sensitised behavioural 
responses may nevertheless underlie motivational aspects of drug seeking 
and contribute to compulsive drug-taking that characterises abuse (Robinson 
& Berridge, 1993, 2003). 
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It has been suggested that escalating dose administrations produce a different 
behavioural profile to that of repeated intermittent administration (Segal & 
Kuczenski, 1999). Animals treated previously with an intermittent or 
escalating dose of amphetamine have exhibited different patterns of FosB and 
c-Fos expression in mesolimbic dopaminergic cell bodies (Murphy, Pezze, 
Russig and Feldo, 2001). Furthermore, following different escalating dose 
administrations of amphetamine Russig, Murphy and Feldon (2005) found a 
reduction in amphetamine produced locomotor activity in day 1 of  the 
withdrawal phase but an increase (behavioural sensitisation) after 5 or 38 
days.  Given different administration schedules of amphetamine lead to 
different behavioural consequences, future research could establish if the 
long term expression of MDMA is evident following an escalating pre-
treatment dosing regimen compared to that of the current intermittent 
exposure. 
 
The current investigation demonstrated cross sensitisation to other dopamine 
agonists suggesting an underlying dopamine mechanism that is common in 
locomotor activating effects of psychostimulants. It has been suggested that 
the action of amphetamine in midbrain DA cell bodies is necessary for the 
induction of behavioural sensitisation. For example, repeated amphetamine 
injections into the ventral tegmental area, but not into the DA terminal field 
in the nucleus accumbens, produce an enhanced locomotor response to 
subsequent peripheral administration of amphetamine (Kalivas and Weber 
1988; Vezina and Stewart 1990). Also, the local microinjection of a DA D1 
receptor antagonist into the ventral tegmental area is sufficient to prevent the 
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development of behavioural sensitisation to systemic amphetamine treatment 
(Stewart and Vezina 1989). Ramos and colleagues (2004, 2005) investigated 
the action of D1 antagonist, SCH23390, in the prevention of development and 
expression of MDMA produced hyperlocomotion. It was argued that 
projections from the prefrontal cortex (PFC) might mediate behavioural 
sensitisation to MDMA and that dopaminergic mechanisms were implicated 
the expression of sensitisation. With the current investigation strongly 
implicating a sensitised D1 receptor and an augmented D2 mechanism in 
response to the current regimen of MDMA administration, it would be 
advantageous for future investigations to examine if these changes translate 
into increases in extracellular dopamine release using a more specific D1 
antagonist as SCH23390 activates 5-HT modulating effects of DA.  
 
Microdialysis analysis in the ventral tegmental area, nucleus accumbens and 
frontal cortex may aid in answering the questions as to what, if any, common 
underlying dopamine mechanisms exist with MDMA and amphetamine 
sensitisation. There have been consistent reports of amphetamine induced 
sensitisation related adaptations in DA neurotransmission in striatal (Kalivas 
and Stewart, 1991; Robinson, 1991; Robinson and Berridge, 1993; White and 
Wolf, 1991) caudate or nucleus accumbens (Kolta et al., 1985, Robinson and 
Becker, 1982; Robinson et al., 1982; Wilcox et al., 1986; Yamada et al., 1988) 
DA release. To date however, few studies have investigated neuroadaptations 
following repeated MDMA administrations that produce behavioural 
sensitisation. Fos expression, which measures protein changes in the 
expression of the immediate early gene c-fos, has been positively correlated 
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with the behavioural consequences of repeated drug exposure in the NAc shell 
(Colussi-Mas & Schenk, 2008) suggesting DA mediated changes from 
repeated intermittent exposure. As experiment two demonstrated alterations in 
receptor mechanism sensitivity and experiment four failed to show any 
changes in gross storage pools of brain amine levels, microdialysis techniques 
may help in the future. Recording relative extracellular levels of brain amines 
in specific areas of the mesolimbic DA pathway may indicate downstream 
alterations in DA overflow responsible for MDMA produced locomotor 
sensitisation. 
 
Changes in dopamine sensitivity may have been expected to increase the 
reinforcing effects of MDMA. When this was tested by examining latency to 
acquisition of self-administration, acquisition was delayed in MDMA pre-
treated animals. Of interest, pre-treatment with MDMA in rats sensitises 
cocaine-induced behavioural responses and increases cocaine-stimulated 
place preference (Horan et al., 2000; Kalivas et al., 1998). As the current pre-
treatment regimen produced sensitised locomotor activation, and may have 
modulated a common dopaminergic mechanism. This raises a question as to 
what, if any, circumstances could decrease latency to acquisition following 
MDMA administration? As mentioned above, different administration 
schedules of amphetamine lead to different behavioural consequences. 
Previous investigations that have looked at changes in potency to 
amphetamine (Piazza et al, 1990) and cocaine (Schenk & Partridge 1997) self 
administration did not use an escalating dosing regimen of stimulant. This 
may suggest that an escalating pre-treatment would not be hypothesised to 
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change the potency of latency to MDMA self-administration acquisition. It 
may have been that the self administration doses selected in the current 
investigation were too high and future studies that commence acquisition on 
a lower dose may show a change in potency resulting in a decrease in latency 
to acquisition.  
 
Throughout the current set of experiments neurochemical changes have been 
induced from exposure to MDMA. This was demonstrated by the reduction 
in 5-HIAA levels. The deficits observed in the current investigation are 
mirrored in a number of MDMA studies that identify neurochemical changes 
following MDMA administration (Battaglia, Yeh, et al., 1988; Commins, et 
al., 1987; Goñi-Allo, et al., 2007; Nair & Gudelsky, 2006). It has become 
increasingly clear that long lasting and perhaps permanent changes in the 
brain underlie maladaptive alterations associated with compulsive drug 
craving (Nestler, 2001). The current testing was conducted under steady state 
conditions whereas most neurochemical adaptations are examined in 
response to a further drug administration (Kalivas, et al. 1998).  
 
Neurochemical analysis under drug conditions may reveal differing 
neurochemical levels to those revealed in the current investigation.  
During amphetamine sensitisation there was a significantly elevated DA 
release in dorsal and ventral striatum (Paulson, Robinson, 1995; Robinson, 
Jurson, Bennett, & Bentgen, 1988) however there was no reported change in 
DA levels in the caudate or accumbens (Segal & Kuczenski, 1992). In future 
investigations, recording of DA release in dorsal and ventral striatum as well 
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as caudate and accumbens brain regions, during the MDMA sensitisation 
regimen, may reveal if there is any overlap in alterations of brain amine 
levels.  
 
Taken together, the current research shows that repeated administration of 
MDMA produces sensitisation to its locomotor activating effects that induced 
lasting dopaminergic and serotonergic neural adaptations.  
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